Compounds useful as RET inhibitors
Selective RET kinase inhibitors address the limitations of current RET inhibitors by minimizing KDR inhibition, providing effective treatment for cancers like MTC and NSCLC with reduced side effects.
Patent Information
- Application Number
- JP2024131113
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-04-13
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current RET inhibitors, such as vandetanib, exhibit significant side effects due to off-target activity and non-selective inhibition of KDR, limiting their clinical benefit in cancers like medullary thyroid carcinoma (MTC) and small cell lung cancer.
Development of selective RET kinase inhibitors that minimize KDR inhibition, offering a more targeted approach to treat proliferative disorders by administering specific compounds that inhibit RET kinase activity.
These selective RET inhibitors provide therapeutic benefits for cancers like MTC and NSCLC with reduced side effects, expanding their clinical use in earlier disease settings.
Smart Images

Figure 2024161432000001 
Figure 2024161432000002 
Figure 2024161432000003
Abstract
Description
[Technical field]
[0001] The present invention relates to certain compounds which function as inhibitors of RET (rearrangement during transfection) kinase enzymatic activity. The present invention also relates to processes for the preparation of these compounds, pharmaceutical compositions containing them, and their use in the treatment of proliferative disorders, such as cancer, and other diseases or conditions in which RET kinase activity is implicated. [Background technology]
[0002] Cancer is caused by uncontrolled and unregulated cell proliferation. What exactly makes a cell malignant and proliferate in an uncontrolled and unregulated manner has been the focus of intense research over the last decades. This research has led to the identification of a large number of molecular targets associated with key metabolic pathways known to be associated with malignant tumors.
[0003] RET (rearranged during transfection) is a receptor tyrosine kinase (RTK) that forms part of a macromolecular receptor complex containing a dimerized RET receptor, two co-receptors and a bound ligand. The glial-derived neurotrophic factor (GDNF) family of ligands binds to RET in association with one of four glycosylphosphatidylinositol (GPI)-anchored GDNF family alpha receptors (GFRα). Binding of the ligand to the corresponding GFRα co-receptor triggers RET dimerization and subsequent transphosphorylation of intracellular signaling cascades. These downstream signaling networks play important roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis.
[0004] Activating mutations in RET have been identified in familial and sporadic forms of medullary thyroid carcinoma (MTC) (Santoro & Carlomagno 2006; Schulmberger et al. 2008; Wells & Santoro 2009) and they correlate with aggressive disease progression (Elisei et al. 2008). Clinical benefit has been observed in MTC patients using the small molecule VEGFR2 / EGFR inhibitor vandetanib (Wells et al. 2011), recently approved by the FDA and EMEA. RET inhibition is a secondary pharmacological effect of this drug, which also targets VEGFR2 (vascular endothelial growth factor receptor, also known as KDR (kinase insert domain receptor)) and EGFR (epidermal growth factor receptor). Clinical benefit in MTC is thought to be due to RET inhibition, but is unfortunately associated with significant side effects (rash, hypertension, diarrhea) due to inhibition of EGFR and / or VEGFR. Moreover, vandetanib also exhibits off-target activity against hERG. Collectively, all of these undesirable pharmacological activities may impede its use in advanced MTC and even its extrapolation to earlier clinical settings (e.g., as an adjuvant).
[0005] Furthermore, several recent publications (Ju et al., 2012; Lipson et al., 2012; Kohno et al., 2012; Wang et al., 2012; Chao et al., 2012) have described various RET fusion translocations (e.g., KIF5B-RET and CCDC6-RET) present in approximately 1% of NSCLC (non-small cell lung cancer) patient samples, which may provide important alternative disease segments in which specific RET inhibitors would provide clinical benefit.
[0006] Therefore, there is a need to develop more selective RET inhibitors, especially those that show less inhibition of KDR.These more selective inhibitors are expected to produce the desired therapeutic benefits associated with RET inhibition without the side effects associated with significant KDR inhibition.Such inhibitors provide better therapeutic potential for cancers such as MTC and NSCLC, and expand the scope of clinical use of RET inhibitors in earlier disease settings.
[0007] It is therefore an object of the present invention to provide further inhibitors of RET kinase enzymatic activity.
[0008] Another object of the present invention is to provide inhibitors of RET kinase enzymatic activity that exhibit greater selectivity for inhibiting RET kinase versus inhibiting KDR. Summary of the Invention
[0009] According to a first aspect of the present invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0010] According to a further aspect of the invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in admixture with a pharma- ceutically acceptable diluent or carrier.
[0011] According to a further aspect of the present invention there is provided a method of inhibiting RET kinase enzymatic activity in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound as defined herein or a pharma-ceutically acceptable salt, hydrate or solvate thereof.
[0012] According to a further aspect of the invention there is provided a method of selectively inhibiting RET kinase enzymatic activity relative to KDR enzymatic activity in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0013] According to a further aspect of the present invention there is provided a method of inhibiting cell proliferation in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound as defined herein or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0014] According to a further aspect of the invention there is provided a method of treating a disease or disorder in which RET kinase activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound as defined herein or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0015] According to a further aspect of the present invention there is provided a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound as defined herein or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0016] According to a further aspect of the present invention there is provided a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound as defined herein or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0017] According to a further aspect of the invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.
[0018] According to a further aspect of the invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a proliferative condition.
[0019] According to a further aspect of the present invention, there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, for use in the treatment of cancer. In certain embodiments, the cancer is a human cancer.
[0020] According to a further aspect of the invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for use in inhibiting RET kinase enzymatic activity.
[0021] According to a further aspect of the invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for use in the selective inhibition of RET kinase enzymatic activity relative to KDR enzymatic activity.
[0022] According to a further aspect of the invention there is provided a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of a disease or disorder in which RET kinase enzymatic activity is implicated.
[0023] According to a further aspect of the invention there is provided the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of a proliferative condition.
[0024] Suitably, the proliferative disorder is cancer, suitably a human cancer (eg medullary thyroid carcinoma (MTC)).
[0025] According to a further aspect of the invention there is provided the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of cancer.
[0026] According to a further aspect of the invention there is provided the use of a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the inhibition of RET kinase enzymatic activity.
[0027] According to a further aspect of the invention there is provided the use of a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the selective inhibition of RET kinase enzymatic activity relative to KDR enzymatic activity.
[0028] According to a further aspect of the invention there is provided the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of a disease or disorder in which RET kinase activity is implicated.
[0029] According to a further aspect of the present invention there is provided a process for preparing a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0030] According to a further aspect of the present invention there is provided a compound obtainable by or obtained by or directly obtained by a process for the preparation of a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0031] According to a further aspect of the present invention there is provided a novel intermediate as defined herein suitable for use in any one of the synthetic methods described herein.
[0032] Features, including any suitable and preferred features, associated with one aspect of the invention may also be features, including any suitable and preferred features, associated with any other aspect of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0033] Detailed Description of the Invention definition Unless otherwise stated, the following terms used in the specification and claims have the following meanings, as explained below.
[0034] References to "treating" or "treatment" should be understood to include prevention as well as the alleviation of established symptoms of a condition. Thus, "treating" or "treatment" of a condition, disorder or condition includes: (1) preventing or delaying the appearance of clinical symptoms of a condition, disorder or condition that develops in a person suffering from or susceptible to the condition, disorder or condition, but who has not yet experienced or exhibited clinical or asymptomatic symptoms of the condition, disorder or condition, (2) inhibiting the condition, disorder or condition, i.e., arresting, reducing or delaying the onset of the disease or its recurrence (in the case of maintenance therapy) or at least one clinical or asymptomatic symptom thereof, or (3) palliating or relieving the disease, i.e., causing a reduction in the condition, disorder or condition or at least one clinical or asymptomatic symptom thereof.
[0035] "Therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" varies depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal being treated.
[0036] In this specification, the term "alkyl" includes both straight-chain and branched-chain alkyl groups. References to individual alkyl groups such as "propyl" are specific for the straight-chain version only, and references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl, and t-butyl. A similar convention applies to other groups, for example, "phenyl(1-6C)alkyl" includes phenyl(1-4C)alkyl, benzyl, 1-phenylethyl, and 2-phenylethyl.
[0037] The term “(m-nC)” or “(m-nC) group” used alone or as a prefix, refers to any group having m through n carbon atoms.
[0038] An "alkylene," "alkenylene," or "alkynylene" group is an alkyl, alkenyl, or alkynyl group that is positioned between and serves to connect two other groups. Thus, "(1-6C)alkylene" refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms, e.g., methylene, ethylene, propylene, 2-methylpropylene, pentylene, and the like.
[0039] "(2-6C)alkenylene" means a linear divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched divalent hydrocarbon radical of 3 to 6 carbon atoms containing at least one double bond, such as, for example, ethenylene, 2,4-pentadienylene, and the like.
[0040] "(2-6C)alkynylene" means a linear divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched divalent hydrocarbon radical of 3 to 6 carbon atoms containing at least one triple bond, such as, for example, ethynylene, propynylene, butynylene, and the like.
[0041] "(3-8C)cycloalkyl" means a hydrocarbon ring containing 3 to 8 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl.
[0042] "(3-8C)cycloalkenyl" means a hydrocarbon ring containing at least one double bond, for example cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, such as 3-cyclohexen-1-yl, or cyclooctenyl.
[0043] "(3-8C)cycloalkyl-(1-6C)alkylene" means a (3-8C)cycloalkyl group covalently linked to a (1-6C)alkylene group, both of which are defined herein.
[0044] The term "halo" or "halogeno" refers to fluoro, chloro, bromo and iodo.
[0045] The term "heterocyclyl", "heterocyclic" or "heterocycle" refers to a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain about 3-12 (preferably 3-7) ring atoms with 1-5 (preferably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles contain 7-17 member atoms, preferably 7-12 member atoms in the ring. The bicyclic heterocycle(s) may be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles containing nitrogen include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, etc. Exemplary sulfur-containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepin. Other heterocycles include dihydro-oxathiol, tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, sulfur oxide heterocycles containing SO or SO2 groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl, such as tetrahydrothienyl 1,1-dioxide and thiomorpholinyl 1,1-dioxide. Suitable alternatives for heterocyclyl groups having one or two oxo (=O) or thioxo (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.Particular heterocyclyl groups are saturated monocyclic 3- to 7-membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As will be appreciated by those skilled in the art, any heterocycle may be linked to another group via any suitable atom, for example via a carbon or nitrogen atom. However, references herein to piperidino or morpholino refer to piperidin-1-yl or morpholin-4-yl rings linked via the ring nitrogen.
[0046] "Bridged ring system" means a ring system in which two rings share more than two atoms, e.g., as described in Advanced Organic Chemistry, by Jerry March, 4 th Edition, Wiley Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane, and quinuclidine.
[0047] "Spiro bicyclic ring system" means that two ring systems share one common spiro carbon atom, i.e., the heterocyclic ring is linked to an additional carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.
[0048] "Heterocyclyl(1-6C)alkyl" means a heterocyclyl group covalently linked to a (1-6C)alkylene group, both of which are defined herein.
[0049] The term "heteroaryl" or "heteroaromatic" refers to an aromatic monocyclic, bicyclic or polycyclic ring incorporating one or more (e.g., 1 to 4, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The term heteroaryl includes both monovalent and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing 5 to 12 ring members, more usually 5 to 10 ring members. Heteroaryl groups can be, for example, 5- or 6-membered monocyclic rings or 9- or 10-membered bicyclic rings, such as fused 5- and 6-membered rings or a bicyclic structure formed from two fused 6-membered rings. Each ring can contain up to about 4 heteroatoms, typically selected from nitrogen, sulfur and oxygen. Typically, heteroaryl rings contain up to 3 heteroatoms, more usually up to 2, e.g., a single heteroatom. In one embodiment, a heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl ring can be basic, as in the case of an imidazole or pyridine, or essentially non-basic, as in the case of an indole or pyrrole nitrogen. Generally, the number of basic nitrogen atoms present in a heteroaryl group, including any amino group substituents on the ring, will be fewer than five.
[0050] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, and isoquinolyl. These include, but are not limited to, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, and imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also includes partially aromatic bicyclic or polycyclic ring systems in which at least one ring is aromatic and one or more of the other ring(s) is non-aromatic saturated or partially saturated ring, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur. Examples of partially aromatic heteroaryl groups include, for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.
[0051] Examples of 5-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.
[0052] Examples of 6-membered heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.
[0053] Bicyclic heteroaryl groups include, for example: A benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; A pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; A pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; A pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; A pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; A pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; A thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; A thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; A furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2, or 3 ring heteroatoms; and It may be a group selected from a cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms.
[0054] Examples of bicyclic heteroaryl groups containing a 6-membered ring fused to a 5-membered ring include, but are not limited to, benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl, and pyrazolopyridinyl groups.
[0055] Examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolidinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.
[0056] "Heteroaryl(1-6C)alkyl" means a heteroaryl group covalently linked to a (1-6C)alkylene group, both of which are defined herein. Examples of heteroaralkyl groups include pyridin-3-ylmethyl, 3-(benzofuran-2-yl)propyl, and the like.
[0057] The term "aryl" refers to a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term "aryl" includes both monovalent and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, and the like. In certain embodiments, the aryl is phenyl.
[0058] The term "aryl(1-6C)alkyl" means an aryl group covalently linked to a (1-6C)alkylene group, both of which are defined herein. Examples of aryl-(1-6C)alkyl groups include benzyl, phenylethyl, and the like.
[0059] The present specification also uses some compound terms to describe groups that contain multiple functionalities. Such terms are understood by those of skill in the art. For example, heterocyclyl(m-nC)alkyl includes (m-nC)alkyl substituted with heterocyclyl.
[0060] The term "optionally substituted" refers to either groups, structures, or molecules that are substituted, as well as those that are not substituted. 1 "One / any CH, CH, CH group or heteroatom (e.g., NH) in the group is optionally substituted" preferably means that R 1 It means that (any) one of the hydrogen radicals of the group is replaced by the associated given group.
[0061] When any substituent is selected from "one or more" groups, this definition is understood to include all substituents selected from one of the specified groups, or substituents selected from two or more of the specified groups.
[0062] The phrase "compounds of the invention" means those compounds disclosed herein both generically and specifically.
[0063] Compounds of the Invention In one aspect, the present invention relates to a compound having the structural formula (I) as shown below, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: [ka] (In the formula: HET is selected from one of the following: [ka] (In the formula, [ka] indicates the point of attachment); R1 is hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -LYQ wherein the group is selected from the group consisting of: L is absent or is (1-5C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or is O, S, SO, SO2, N(R a ), C(O), C(O)O, OC(O), C(O)N(R a ), N(R a )C(O),N(R a )C(O)N(R b ), N(R a )C(O)O,OC(O)N(R a ), S(O)2N(R a ), or N(R a )SO2 (where R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d )R c , N(R d )C(O)R c , S(O) y Rc (y is 0, 1, or 2), SO2N(R d )R c , N(R d )SO2R c , Si(R d )(R c )R e or (CH2) z NR d R c (z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R c and R d may be linked together with the nitrogen atom to which they are attached such that they form a 4- to 7-membered heterocyclic ring optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano or hydroxy; or Q is a group represented by the formula: -L1-L Q1 -Z1 wherein: L1 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; L Q1 is absent or O, S, SO, SO2, N(R f ), C(O), C(O)O, OC(O), C(O)N(R f ), N(R f )C(O),N(R g )C(O)N(R f ), N(R f )C(O)O,OC(O)N(R f ), S(O)2N(R f ), or N(R f )SO2 (where R f and R gare each independently selected from hydrogen or (1-2C)alkyl; Z1 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z1 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR h R i , OR h , C(O)R h , C(O)OR h , O.C.(O)R h , C(O)N(R i )R h , N(R i )C(O)R h , S(O) y R h (y is 0, 1, or 2), SO2N(R i )R h , N(R i )SO2R h or (CH2) z NR i R h (z is 1, 2 or 3); R h and R i are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); R 1a and R 1b are each selected from H, (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl or mercapto; W is O, S or NR 1 (In the formula, R 1is selected from H or (1-2C)alkyl); Bonds a, b, c and d are independently selected from single or double bonds; X1 and X2 each independently represent N or CR when bond a is a double bond. j or NR if bond a is a single bond. k Or CR j R k Selected from; (In the formula, R j is hydrogen, halo, (1-4C) alkyl, (1-4C) alkoxy, amino, (1-4C) alkylamino, (1-4C) dialkylamino, cyano, (2C) alkynyl, C(O)R j1 , C(O)OR j1 , O.C.(O)R j1 , C(O)N(R j2 )R j1 , N(R j2 )C(O)R j1 , S(O) y R j1 (y is 0, 1, or 2), SO2N(R j2 )R j1 , N(R j2 )SO2R j1 or (CH2) z NR j1 R j2 (z is 1, 2 or 3); said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R k and R j is independently selected from hydrogen or (1-4C)alkyl; R j1 and R j2 are each independently selected from hydrogen or (1-4C)alkyl; X3 is N or CR when bond b is a double bond. l or NR if bond b is a single bond. m Or CR l R mSelected from; (In the formula, R l is hydrogen, halo, (1-4C) alkyl, (1-4C) alkoxy, amino, (1-4C) alkylamino, (1-4C) dialkylamino, cyano, (2C) alkynyl, C(O)R l1 , C(O)OR l1 , O.C.(O)R l1 , C(O)N(R l2 )R l1 , N(R l2 )C(O)R l1 , S(O) y R l1 (y is 0, 1, or 2), SO2N(R l2 )R l1 , N(R l2 )SO2R l1 or (CH2) z NR l2 R l1 (z is 1, 2 or 3); said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R l and R m is independently selected from hydrogen or (1-4C)alkyl; R l1 and R l2 are each independently selected from hydrogen or (1-4C)alkyl; X4 is N or CR when bond d is a double bond. n or NR if bond d is a single bond. o Or CR n R o Selected from; (In the formula, R n is hydrogen, halo, (1-4C) alkyl, (1-4C) alkoxy, amino, (1-4C) alkylamino, (1-4C) dialkylamino, cyano, (2C) alkynyl, C(O)R n1 , C(O)OR n1 , O.C.(O)R n1 , C(O)N(R n2 )Rn1 , N(R n2 )C(O)R n1 , S(O) y R n1 (y is 0, 1, or 2), SO2N(R n2 )R n1 , N(R n2 )SO2R n1 or (CH2) z NR n1 R n2 (z is 1, 2 or 3); said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R n and R o is independently selected from hydrogen or (1-4C)alkyl; R n1 and R n2 are each independently selected from hydrogen or (1-4C)alkyl; R2 is hydrogen, (1-4C)alkyl or a group of the formula: -L2-Y2-Q2 wherein: L2 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; Y2 is absent or C(O), C(O)O, C(O)N(R p )(wherein, R p is selected from hydrogen or (1-4C)alkyl; Q2 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q2 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR q R r , OR q (In the formula, R q and R rare optionally further substituted by one or more substituents independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); R3 is a group represented by the formula: -Y3-Q3 wherein: Y3 is C(O), C(O)N(R s ), N(R s )(O)C, C(O)OR s , O.C.(O)CR s , triazole, oxadiazole or tetrazole (wherein R s is selected from hydrogen or (1-2C)alkyl; Q3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q3 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q3 is a group of the formula: -L4-L Q4 -Z4 wherein: L4 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; L Q4 is absent or O, S, SO, SO2, N(R v ), C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R w )C(O)N(Rv ), N(R v )C(O)O,OC(O)N(R v ), S(O)2N(R v ), or N(R v )SO2 (where R v and R w are each independently selected from hydrogen or (1-2C)alkyl; Z4 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR x R y , OR x , C(O)R x , C(O)OR x , O.C.(O)R x , C(O)N(R y )R x , N(R y )C(O)R x , S(O) y R x (y is 0, 1, or 2), SO2N(R y )R x , N(R y )SO2R x or (CH2) z NR x R y (z is 1, 2 or 3); R x and R y are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); However, only one or two of X1, X2, X3 or X4 can be N).
[0064] Particular compounds of the invention include, for example, compounds of formula I, or pharma- ceutically acceptable salts, hydrates and / or solvates thereof, where, unless otherwise stated, HET, R, R 1a , R 1b , W, bonds a, b, c and d, X1, X2, X3, X4, R2 and R3, and any associated substituents, each having any of the meanings defined above or in any of the following paragraphs (1) to (44): (1) HET is selected from one of the following: [ka] (2) HET is selected from one of the following: [ka] (3) H.E.T. [ka] Is: (4) R1 is hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -LYQ wherein: L is absent or is (1-5C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or is O, S, SO, SO2, N(R a ), C(O), C(O)O, OC(O), C(O)N(R a ), N(R a )C(O), S(O)2N(R a ), or N(R a )SO2 (where R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d )R c , N(R d )C(O)R c , S(O) y R c (y is 0, 1, or 2), SO2N(R d )R c , N(R d )SO2R c , Si(R d )(R c )R e or (CH2) z NR d R c (z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R c and R d may be linked together with the nitrogen atom to which they are attached such that they form a 4- to 7-membered heterocyclic ring optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano or hydroxy; or Q is a group represented by the formula: -L1-L Q1 -Z1 wherein: L1 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl; L Q1 is absent or O, S, SO, SO2, N(R f ), C(O), C(O)O, OC(O), C(O)N(R f ), N(R f )C(O),N(R f )C(O)O,S(O)2N(R f ), or N(R f )SO2 (where R f and R g are each independently selected from hydrogen or (1-2C)alkyl; Z1 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z1 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR h R i OR h (In the formula, R h and R i are each independently selected from hydrogen, 1-4C) alkyl or (3-6C) cycloalkyl) optionally substituted with one or more substituents selected from; (5) R1 is hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -LYQ wherein: L is absent or is (1-3C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or O, N(R a ), C(O), C(O)O, OC(O), C(O)N(R a ), N(R a )C(O), S(O)2N(R a ), or N(R a )SO2 (where R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d )R c , N(R d )C(O)R c , S(O) y R c (y is 0, 1, or 2), SO2N(R d )R c , N(R d )SO2R c , Si(R d )(R c )R e or (CH2) z NR d R c (z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R c and R dmay be linked together with the nitrogen atom to which they are attached such that they form a 4- to 7-membered heterocyclic ring optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano or hydroxy; or Q is a group represented by the formula: -L1-L Q1 -Z1 wherein: L1 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl; L Q1 is non-existent or N(R f ), C(O), C(O)O, OC(O), C(O)N(R f ), N(R f )C(O) or N(R f )C(O)O(wherein, R f and R g are each independently selected from hydrogen or (1-2C)alkyl; Z1 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z1 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, (3-6C)cycloalkyl, NR h R i OR h (In the formula, R h and R i are each independently selected from hydrogen, (1-4C)alkyl or cycloalkyl) optionally substituted with one or more substituents selected from; (6) R1 represents hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -LYQ wherein: L is absent or is (1-3C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or O, N(R a ), C(O), C(O)O, OC(O), C(O)N(R a ), N(R a )C(O), S(O)2N(R a ), or N(R a )SO2 (where R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d )R c , N(R d )C(O)R c , S(O) y R c (y is 0, 1, or 2), SO2N(R d )R c , N(R d )SO2R c , Si(R d )(R c )R e or (CH2) z NR d R c (z is 1, 2, or 3); c , R d and Re are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R c and R d may be linked together with the nitrogen atom to which they are attached such that they form a 4- to 7-membered heterocyclic ring optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, or hydroxy; (7) R1 represents hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -LYQ wherein: L is absent or is (1-3C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl or oxo; Y is absent or is C(O), C(O)O, OC(O), C(O)N(R a ) or N(R a )C(O)(wherein, R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d )R c , N(R d )C(O)R c , S(O)y R c (y is 0, 1, or 2), SO2N(R d )R c , N(R d )SO2R c , Si(R d )(R c )R e or (CH2) z NR d R c (z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl, or (3-6C)cycloalkyl; (8) R1 is selected from hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl, or heterocyclyl; each of said substituents is selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d )R c , N(R d )C(O)R c , S(O) y R c (y is 0, 1, or 2), SO2N(R d )R c , N(R d )SO2R c , Si(R d )(R c )R e or (CH2) z NR d R c(z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; (9) R1 is selected from hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-6C)alkyl, (3-10C)cycloalkyl, or heterocyclyl; each of said substituents is selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c or Si(R d )(R c )R e and optionally further substituted by one or more substituents independently selected from c , R d and R e are each independently selected from hydrogen or (1-6C)alkyl; (10) R1 is selected from hydrogen, (1-6C)alkyl or (3-10C)cycloalkyl; each of said substituents is selected from (1-4C)alkyl, halo, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, NR c R d , OR c or Si(R d )(R c )R e and optionally further substituted by one or more substituents independently selected from c , R d and R e are each independently selected from hydrogen or (1-4C)alkyl; (11) R1 is selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; each of said substituents is selected from (1-4C)alkyl, OR c or Si(R d)(R c )R e and optionally further substituted by one or more substituents independently selected from c , R d and R e are each independently selected from hydrogen or (1-2C)alkyl; (12) R1 is tert-butyl; (13)R 1a and R 1b are each selected from H, (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, or hydroxy; (14)R 1a and R 1b are each selected from H, (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)alkoxy, amino, cyano, or hydroxy; (15)R 1a and R 1b are each selected from H or (1-4C)alkyl; (16)R 1a and R 1b are H, respectively; (17) W is selected from O or S; (18) W is O; (19) Bonds a, b, c and d are all double bonds; (20) Bonds a, b, c and d are all single bonds; (21) X1 and X2 each independently represent N or CR when bond a is a double bond. j or NR if bond a is a single bond. k Or CR j R k Selected from; (In the formula, R jis selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino, cyano, (2C)alkynyl, wherein said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R k and R j is independently selected from hydrogen or (1-4C)alkyl; (22) X1 and X2 each independently represent N or CR when bond a is a double bond. j or NR if bond a is a single bond. k Or CR j R k Selected from; (In the formula, R j is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino, cyano, (2C)alkynyl; R k and R j is independently selected from hydrogen or (1-4C)alkyl; (23) X1 and X2 each independently represent N or CR. j Bond a is a double bond; R j is selected from hydrogen, halo, (1-4C)alkyl or amino; (24) X1 and X2 are CR j Bond a is a double bond; R j is selected from hydrogen, halo or (1-4C)alkyl; (25) X1 and X2 are CH, and bond a is a double bond; (26) X3 is N or CR when bond b is a double bond. l or NR if bond b is a single bond. m Or CR l R m Selected from; (In the formula, R l is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino, cyano, (2C)alkynyl, wherein said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R l and R m is independently selected from hydrogen or (1-4C)alkyl; (27) X3 is N or CR when bond b is a double bond. l or NR if bond b is a single bond. m Or CR l R m Selected from; (In the formula, R l is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino, cyano, (2C)alkynyl; R l and R m is independently selected from hydrogen or (1-4C)alkyl; (28) X3 is N or CR l bond b is a double bond; R l is selected from hydrogen, halo, (1-4C)alkyl or amino; (29) X3 is CR l and bond b is a double bond; R l is selected from hydrogen, halo, (1-4C)alkyl or amino; (30) X3 is CH and bond b is a double bond; (31) X4 is N or CR when bond d is a double bond. n or NR if bond d is a single bond. o Or CR n R o Selected from; (In the formula, R nis selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino, cyano, (2C)alkynyl, wherein said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R n and R o is independently selected from hydrogen or (1-4C)alkyl; (32) X4 is N or CR when bond d is a double bond. n or NR if bond d is a single bond. o Or CR n R o Selected from; (In the formula, R n is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino, cyano, (2C)alkynyl; R n and R o is independently selected from hydrogen or (1-4C)alkyl; (33) X4 is N or CR n bond d is a double bond; R n is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino or cyano, (2C)alkynyl; (34) X4 is CR n and bond d is a double bond; R n is selected from hydrogen, halo, (1-4C)alkyl or amino; (35) R2 is hydrogen, (1-4C)alkyl or a group of the formula: -L2-Y2-Q2 wherein: L2 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; Y2 is absent or C(O), C(O)O, C(O)N(R p )(wherein, R p is selected from hydrogen or (1-4C)alkyl; Q2 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; Q2 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, NR q R r , OR q (In the formula, R q and R r are optionally further substituted by one or more substituents independently selected from: (36) R2 is hydrogen, (1-4C)alkyl or a group of the formula: -Y2-Q2 wherein: Y2 is absent or C(O), C(O)O, C(O)N(R p )(wherein, R p is selected from hydrogen or (1-4C)alkyl; Q2 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; Q2 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, NR q R r , OR q (In the formula, R q and R r are optionally further substituted by one or more substituents independently selected from: (37) R2 is hydrogen, (1-4C)alkyl or a group of the formula: -Y2-Q2 wherein: Y2 is C(O)N(R p )(wherein, R pis selected from hydrogen or (1-4C)alkyl; Q2 is (1-6C)alkyl, aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; Q2 is optionally further substituted by one or more substituents independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano or hydroxy; (38) R2 is selected from hydrogen or (1-4C)alkyl; (39) R2 is hydrogen; (40) R3 represents a group represented by the formula: -Y3-Q3 wherein: Y3 is C(O), C(O)N(R s ), N(R s )(O)C, C(O)OR s , O.C.(O)CR s (In the formula, R s is selected from hydrogen or (1-2C)alkyl; Q3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q3 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q3 is a group of the formula: -L4-L Q4 -Z4 wherein: L4 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; L Q4 is non-existent or O,N(R v ), C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O), S(O)2N(R v ), or N(R v )SO2 (where R v and R w are each independently selected from hydrogen or (1-2C)alkyl; Z4 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR x R y , OR x , C(O)R x , C(O)OR x , O.C.(O)R x , C(O)N(R y )R x , N(R y )C(O)R x , S(O) y R x (y is 0, 1, or 2), SO2N(R y )R x , N(R y )SO2R x or (CH2) z NR x R y (z is 1, 2 or 3); R x and R yare each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); (41) R3 represents the formula: -Y3-Q3 wherein: Y3 is C(O)N(R s )(wherein, R s is selected from hydrogen or (1-2C)alkyl; Q3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q3 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q3 is a group of the formula: -L4-L Q4 -Z4 wherein: L4 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; L Q4 is absent or O, S, SO, SO2, N(R v ), C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O),N(R w )C(O)N(R v ), N(R v )C(O)O,OC(O)N(R v ), S(O)2N(R v ), or N(R v )SO2 (where R vand R w are each independently selected from hydrogen or (1-2C)alkyl; Z4 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR x R y , OR x , C(O)R x , C(O)OR x , O.C.(O)R x , C(O)N(R y )R x , N(R y )C(O)R x , S(O) y R x (y is 0, 1, or 2), SO2N(R y )R x , N(R y )SO2R x or (CH2) z NR x R y (z is 1, 2 or 3); R x and R y are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); (42) R3 represents the formula: -Y3-Q3 wherein: Y3 is C(O)NH; Q3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q3 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q3 is a group of the formula: -L4-L Q4 -Z4 wherein: L4 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from a (1-2C)alkyl or an oxo; L Q4 is non-existent or O,N(R v ), C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O), S(O)2N(R v ), or N(R v )SO2 (where R v and R w are each independently selected from hydrogen or (1-2C)alkyl; Z4 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR x R y , OR x and optionally substituted with one or more substituents selected from: x and R y are each independently selected from hydrogen or (1-4C)alkyl); (43) R3 represents a group represented by the formula: -Y3-Q3 wherein: Y3 is C(O)NH; Q3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q3 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q3 is a group of the formula: -L4-L Q4 -Z4 wherein: L4 is absent or is a (1-3C)alkylene optionally substituted with one or more substituents selected from (1-2C)alkyl; L Q4 is non-existent or O,N(R v )(wherein, R v is selected from hydrogen or (1-2C)alkyl; Z4 is hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl; Z4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, (3-6C)cycloalkyl, NR x R y , OR x and optionally substituted with one or more substituents selected from: x and R y are each independently selected from hydrogen or (1-4C)alkyl); (44) R3 represents the formula: -Y3-Q3 wherein: Y3 is C(O)NH; Q3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; Q3 is (1-4C)alkyl, halo, (1-4C)haloalkyl, amino, cyano, hydroxy, NR t R u , OR t (In the formula, R t and R u are optionally further substituted by one or more substituents independently selected from hydrogen or (1-4C)alkyl; or Q3 is a group of the formula: -L4-L Q4 -Z4 wherein: L4 is absent or is (1-2C)alkylene; L Q4 is absent or selected from O; Z4 is hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl; Z4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)alkoxy, amino, hydroxy, (3-6C)cycloalkyl, NR x R y , OR x and optionally substituted with one or more substituents selected from: x and R y are each independently selected from hydrogen or (1-4C)alkyl).
[0065] Suitably, a heteroaryl or heterocyclyl group as defined herein is a monocyclic heteroaryl or heterocyclyl group containing 1, 2 or 3 heteroatoms selected from N, O or S.
[0066] Suitably, the heteroaryl is a 5 or 6 membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from N, O or S.
[0067] Preferably, the heterocyclyl group is a 4-, 5- or 6-membered heterocyclyl ring containing 1, 2 or 3 heteroatoms selected from N, O or S. Most preferably, the heterocyclyl group is a 5-, 6- or 7-membered ring containing 1, 2 or 3 heteroatoms selected from N, O or S [e.g., morpholinyl (e.g. 4-morpholinyl), pyridinyl, piperazinyl, homopiperazinyl or pyrrolidinonyl].
[0068] Preferably, the aryl group is phenyl.
[0069] Preferably, HET is as defined in any one of paragraphs (1) to (3). Most preferably, HET is as defined in paragraph (3).
[0070] Preferably, R1 is as defined in any one of paragraphs (4) to (12). More preferably, R1 is as defined in any one of paragraphs (8) to (12). Most preferably, R1 is as defined in paragraph (12).
[0071] Preferably, R 1a and R 1b is as defined in any one of paragraphs (13) to (16). Most preferably, R 1a and R 1b is as defined in paragraph (16).
[0072] Preferably, W is as defined in any one of paragraphs (17) to (18). Most preferably, W is as defined in paragraph (18).
[0073] Preferably, bonds a, b, c and d are as defined in any one of paragraphs (19) to (20). Preferably, bonds a, b, c and d are as defined in paragraph (19).
[0074] Preferably, X1 and X2 are as defined in any one of paragraphs (21) to (25). Most preferably, X1 and X2 are as defined in paragraph (25).
[0075] Preferably, X3 is as defined in any one of paragraphs (26) to (30). Most preferably, X3 is as defined in paragraph (30).
[0076] Preferably, X4 is as defined in any one of paragraphs (31) to (34). Most preferably, X4 is as defined in paragraph (34).
[0077] Preferably, R2 is as defined in any one of paragraphs (35) to (39). More preferably, R2 is as defined in any one of paragraphs (37) to (39). Most preferably, R2 is as defined in paragraph (39).
[0078] Preferably, R3 is as defined in any one of paragraphs (40) to (44). Most preferably, R3 is as defined in paragraph (44).
[0079] In a particular group of compounds of the invention, the compounds have the structural formula Ia (subdefinition of formula (I)) shown below, or a pharma- ceutically acceptable salt, hydrate and / or solvate thereof: [ka] (In the formula, HET, R1, R 1a , R 1b , bonds a, b, c and d, X1, X2, X3, X4, R2, Q3 and R s each have one of the meanings defined herein).
[0080] In an embodiment of the compound of formula Ia: HET is as defined in any one of paragraphs (1) to (3) above; R1 is as defined in any one of paragraphs (4) to (12) above; R 1a and R 1b is as defined in any one of paragraphs (13) to (16) above; Bonds a, b, c and d are as defined in any one of paragraphs (19) to (20) above; X1 and X2 are as defined in any one of paragraphs (21) to (25) above; X3 is as defined in any one of paragraphs (26) to (30) above; X4 is as defined in any one of paragraphs (31) to (34) above; R2 is as defined in any one of paragraphs (35) to (39) above; R s is as defined in any one of paragraphs (40) to (41) above; Q3 is as defined in any one of paragraphs (40) to (44) above.
[0081] In another embodiment of the compound of formula Ia: HET is as defined in paragraph (3) above; R1 is as defined in paragraph (12) above; R 1a and R 1b is as defined in paragraph (16) above; Bonds a, b, c and d are as defined in paragraph (20) above; X1 and X2 are as defined in paragraph (25) above; X3 is as defined in paragraph (30) above; X4 is as defined in paragraph (34) above; R2 is as defined in paragraph (39) above; R3 is as defined above in paragraph (44).
[0082] In a particular group of compounds of the invention, the compounds have the structural formula Ib (subdefinition of formula (I)) shown below, or a pharma- ceutically acceptable salt, hydrate and / or solvate thereof: [ka] (Wherein, R1, bonds a, b, c and d, X1, X2, X3, X4, R2, Q3 and R s each have one of the meanings defined herein).
[0083] In an embodiment of the compound of formula Ib: R1 is as defined in any one of paragraphs (4) to (12) above; Bonds a, b, c and d are as defined in any one of paragraphs (19) to (20) above; X1 and X2 are as defined in any one of paragraphs (21) to (25) above; X3 is as defined in any one of paragraphs (26) to (30) above; X4 is as defined in any one of paragraphs (31) to (34) above; R2 is as defined in any one of paragraphs (35) to (39) above; R s is as defined in any one of paragraphs (40) to (41) above; Q3 is as defined in any one of paragraphs (40) to (44) above.
[0084] In another embodiment of the compound of formula Ib: R1 is as defined in paragraph (12) above; Bonds a, b, c and d are as defined in paragraph (20) above; X1 and X2 are as defined in paragraph (25) above; X3 is as defined in paragraph (30) above; X4 is as defined in paragraph (34) above; R2 is as defined in paragraph (39) above; R s is as defined in paragraph (41) above; Q3 is as defined in paragraph (44) above.
[0085] In a particular group of compounds of the invention, the compounds have the structural formula Ic (subdefinition of formula (I)) shown below, or a pharma- ceutically acceptable salt, hydrate and / or solvate thereof: [ka] (Wherein, R1, X1, X2, X3, X4, R2, Q3 and Rs each have one of the meanings defined herein).
[0086] In an embodiment of the compound of formula Ic: R1 is as defined in any one of paragraphs (4) to (12) above; X1 and X2 are as defined in any one of paragraphs (23) to (25) above; X3 is as defined in any one of paragraphs (28) to (30) above; X4 is as defined in any one of paragraphs (33) to (34) above; R2 is as defined in any one of paragraphs (35) to (39) above; R s is as defined in any one of paragraphs (40) to (41) above; Q3 is as defined in any one of paragraphs (40) to (44) above.
[0087] In another embodiment of the compound of formula Ic: R1 is as defined in paragraph (12) above; X1 and X2 are as defined in paragraph (25) above; X3 is as defined in paragraph (30) above; X4 is as defined in paragraph (34) above; R2 is as defined in paragraph (39) above; R s is as defined in paragraph (41) above; Q3 is as defined in paragraph (44) above.
[0088] In a particular group of compounds of the invention, the compound has the structural formula Id shown below (subdefinition of formula (I)), or a pharma- ceutically acceptable salt, hydrate and / or solvate thereof: [ka] (wherein R1, X4, R2 and Q3 each have one of the meanings defined herein).
[0089] In an embodiment of the compound of formula Id: R1 is as defined in any one of paragraphs (4) to (12) above; X4 is as defined in any one of paragraphs (33) to (34) above; R2 is as defined in any one of paragraphs (35) to (39) above; Q3 is as defined in any one of paragraphs (40) to (44) above.
[0090] In another embodiment of the compound of formula Id: R1 is as defined in paragraph (12) above; X4 is as defined in paragraph (34) above; R2 is as defined in paragraph (39) above; Q3 is as defined in paragraph (44) above.
[0091] Particular compounds of the invention include any of the compounds exemplified in this application, or a pharma- ceutically acceptable salt or solvate thereof, in particular any of the following: 6-(4-amino-1-cyclopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-ethyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,5-dimethylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N,3-dimethyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-fluoro-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclobutyl-1H-indole-2-carboxamide; 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-methylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethoxy-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-fluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-chloro-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-hydroxyethyl)pyrazol-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-pyridyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-pyridyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-fluoroethyl)pyrazol-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-methoxyethyl)pyrazol-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-ethylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-methylthiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isoxazol-4-yl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-5-yl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-thienyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-hydroxyethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-phenyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methoxyethoxy)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-methylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(cyclopropylmethoxy)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethoxy-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,2-difluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(cyclopropylmethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-phenethyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-benzyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isobutyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-fluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methoxy-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-propyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methoxyethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-butyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isopropyl-1H-indole-2-carboxamide; 6-[4-amino-1-(3-hydroxy-3-methyl-cyclopentyl)pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N,3-dimethyl-1H-indole-2-carboxamide; 6-[4-amino-1-(3-methoxypropyl)pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-cyclobutyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; or tert-Butyl 3-[4-amino-3-[2-(methylcarbamoyl)-1H-indol-6-yl]pyrazolo[3,4-d]pyrimidin-1-yl]azetidine-1-carboxylate.
[0092] The various functional groups and substituents which make up the compound of formula (I) are typically selected so that the molecular weight of the compound of formula (I) does not exceed 1000. More usually, the molecular weight of the compound is less than 900, for example, less than 800, or less than 750, or less than 700, or less than 650. More preferably, the molecular weight is less than 600, for example, 550 or less.
[0093] Suitable pharma- ceutically acceptable salts of the compounds of the invention are, for example, acid addition salts of the compounds of the invention which are sufficiently basic, for example, with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid, methanesulfonic acid or maleic acid.Suitable pharma- ceutically acceptable salts of the compounds of the invention which are sufficiently acidic are also alkali metal salts, for example, sodium or potassium salts, alkaline earth metal salts, for example, calcium or magnesium salts, ammonium salts or salts with organic bases which provide a pharma- ceutically acceptable cation, for example, salts with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris(2-hydroxyethyl)amine.
[0094] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are called "isomers". Isomers that differ in the arrangement of their atoms in space are called "stereoisomers". Stereoisomers that are not mirror images of one another are called "diastereomers" and those that are non-superimposable mirror images of one another are called "enantiomers". When a compound has an asymmetric center, for example, when it is bonded to four different groups, there can be a pair of enantiomers. Enantiomers can be characterized by the absolute configuration of their asymmetric center and are described by the R and S ordering rules of Cahn and Prelog or by the way the molecule rotates the plane of polarized light and are designated as dextrorotatory or levorotatory (i.e., as (+) or (-) isomers, respectively). Chiral compounds can exist either as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture".
[0095] The compounds of the present invention may have one or more asymmetric centers; therefore, such compounds may be produced as individual (R) or (S) stereoisomers or as mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures thereof (racemic or otherwise). Methods for the determination of stereochemistry and separation of stereoisomers are well known in the art (see the discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example, by synthesis from optically active starting materials or by resolution of racemates. Some of the compounds of the present invention may have geometric isomeric centers (E and Z isomers). It is to be understood that the present invention encompasses all optical diastereoisomers and geometric isomers and mixtures thereof that have antiproliferative activity.
[0096] The present invention also encompasses compounds of the present invention as defined herein that contain one or more isotopic substitutions. For example, H can be any isotopic form, including 1H, 2H (D), and 3H (T); C can be any isotopic form, including 12C, 13C, and 14C; O can be any isotopic form, including 16O and 18O; and so forth.
[0097] It is also to be understood that certain compounds of formula (I) may exist in solvated as well as unsolvated forms, such as, for example, hydrated forms, etc. It is to be understood that the present invention encompasses all such solvated forms that possess antiproliferative activity.
[0098] It is also to be understood that certain compounds of formula I may exhibit polymorphism, and that the invention encompasses all such forms which possess antiproliferative activity.
[0099] Compounds of formula I may exist in a number of different tautomeric forms, and reference to a compound of formula I includes all such forms. For the avoidance of doubt, where a compound may exist in one of several tautomeric forms and only one is specifically described or shown, all others are nevertheless encompassed by formula I. Examples of tautomeric forms include keto, enol, and enolate forms, such as, for example, the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / acy-nitrilo. [ka]
[0100] Compounds of formula I that contain amine functionality can also form N-oxides. Reference herein to compounds of formula I that contain amine functionality also includes N-oxides. When a compound contains several amine functionalities, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are the N-oxides of tertiary amines or nitrogen atoms of nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., a peroxycarboxylic acid). See, for example, Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More specifically, N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), in which an amine compound is reacted with m-chloroperoxybenzoic acid (mCPBA) in an inert solvent such as dichloromethane.
[0101] The compounds of formula (I) may be administered in the form of prodrugs that are broken down in the human or animal body to release the compounds of the present invention. Prodrugs may be used to change the physical properties and / or pharmacokinetic properties of the compounds of the present invention. Prodrugs may be formed when the compounds of the present invention contain a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include in vivo cleavable ester derivatives that may be formed at the carboxy or hydroxy group in the compounds of formula (I) and in vivo cleavable amide derivatives that may be formed at the carboxy or amino group in the compounds of formula (I).
[0102] The present invention therefore includes those compounds of formula (I) as defined above when made available by organic synthesis and when made available in the human or animal body by cleavage of a prodrug thereof. The present invention therefore includes those compounds of formula I produced by organic synthetic means, and also such compounds produced in the human or animal body by metabolism of a precursor compound that is a compound of formula (I) may be synthetically produced compounds or metabolically produced compounds.
[0103] Suitable pharma- ceutically acceptable prodrugs of the compounds of formula (I) are those that are based on sound medical judgment as being suitable for administration to the human or animal body without undesirable pharmacological activity and without undue toxicity.
[0104] Various forms of prodrugs are described, for example, in the following documents: a)Methods in Enzymology,Vol.42,p.309-396,edited by K.Widder,et al.(Academic Press,1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987。
[0105] Suitable pharma- ceutically acceptable prodrugs of a compound of formula I having a carboxy group are, for example, in vivo cleavable esters thereof. In vivo cleavable esters of a compound of formula I containing a carboxy group are, for example, pharma- ceutically acceptable esters which are cleaved in the human or animal body to produce the parent acid. Suitable pharma- ceutically acceptable esters for carboxy include C1-6 alkyl esters such as methyl, ethyl and tert-butyl, C1-6 alkoxymethyl esters such as methoxyethyl ester, C1-6 alkanoyloxymethyl esters such as pivaloyloxymethyl ester, 3-phthalidyl ester, C3-8 cycloalkylcarbonyloxy-C1-6 alkyl esters such as cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl ester, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl ester and C1-6 alkoxycarbonyloxy-C1-6 alkyl esters such as methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl ester.
[0106] Suitable pharma- ceutically acceptable prodrugs of the compound of formula (I) with hydroxy group are, for example, its in vivo cleavable ester or ether. The in vivo cleavable ester or ether of the compound of formula I containing hydroxy group is, for example, a pharma- ceutically acceptable ester or ether that is cleaved in the human or animal body to generate the parent hydroxy compound. Suitable pharma-ceutically acceptable ester-forming groups for hydroxy group include inorganic esters, for example, phosphate esters (including phosphoramide cyclic esters). More suitable pharma-ceutically acceptable ester-forming groups for hydroxy group include C1-10 alkanoyl groups, for example, acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, C1-10 alkoxycarbonyl groups, for example, ethoxycarbonyl, N,N-(C1-6)2 carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C1-4 alkyl)piperazin-1-ylmethyl. Suitable pharma-ceutically acceptable ether forming groups for hydroxy groups include α-acyloxyalkyl groups, such as acetoxymethyl and pivaloyloxymethyl groups.
[0107] Suitable pharma- ceutically acceptable pro-drugs of a compound of formula (I) bearing a carboxy group are, for example, its in vivo cleavable amides, for example amides formed with amines such as ammonia, C1-4 alkylamines such as methylamine, (C1-4 alkyl)2 amines such as dimethylamine, N-ethyl-N-methylamine or diethylamine, C1-4 alkoxy-C2-4 alkylamines such as 2-methoxyethylamine, phenyl-C1-4 alkylamines such as benzylamine and amino acids such as glycine or esters thereof.
[0108] Suitable pharmaceutically acceptable prodrugs of the compounds of formula I with amino group are, for example, its in vivo cleavable amide derivatives.Suitable pharmaceutically acceptable amides from amino group include, for example, C1-10 alkanoyl groups, such as acetyl, benzoyl, phenylacetyl and substituted benzoyl, and amides formed with phenylacetyl groups.Examples of ring substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C1-4 alkyl)piperazin-1-ylmethyl.
[0109] The in vivo effects of the compounds of formula (I) may be exerted in part by one or more metabolic products formed in the human or animal body after administration of the compounds of formula (I).As mentioned above, the in vivo effects of the compounds of formula (I) may also be exerted by metabolism of precursor compounds (prodrugs).
[0110] The present invention may relate to any compound or particular group of compounds defined herein by any preferred or advantageous feature or otherwise with respect to a particular embodiment, but the present invention may also relate to any compound or particular group of compounds that specifically excludes any said preferred or advantageous feature or particular embodiment.
[0111] Suitably, the present invention excludes any individual compound that does not have biological activity as defined herein.
[0112] synthesis The compounds of the present invention may be prepared by any suitable technique known in the art. Specific processes for the preparation of these compounds are further described in the accompanying Examples.
[0113] In the description of synthetic methods provided herein, and in any referenced synthetic methods used to prepare starting materials, it is understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment, and work-up procedures, can be selected by one of ordinary skill in the art.
[0114] It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions employed.
[0115] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituents to prevent their undesired reactions. The skilled chemist will understand when such protection is necessary and how such protecting groups may be put in place and subsequently removed.
[0116] For examples of protecting groups, see one of the many general texts on the subject, such as 'Protective Groups in Organic Synthesis' by Theodora Green (Publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such method being selected so as to effect removal of the protecting group with minimal disturbance to groups elsewhere in the molecule.
[0117] Thus, if reactants include groups such as amino, carboxy or hydroxy, it may be desirable to protect the group in some of the reactions described herein.
[0118] For example, suitable protecting groups for amino or alkylamino groups are, for example, acyl groups, such as alkanoyl groups, for example acetyl, alkoxycarbonyl groups, for example methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl groups, arylmethoxycarbonyl groups, for example benzyloxycarbonyl, or aroyl groups, for example benzoyl groups. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or alkoxycarbonyl groups or aroyl groups, can be removed, for example, by hydrolysis with a suitable base, for example an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively, acyl groups such as the tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid, and arylmethoxycarbonyl groups such as the benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon, or by treatment with a Lewis acid, for example borontris (trifluoroacetate).A suitable alternative protecting group for a primary amino group is, for example, the phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or hydrazine.
[0119] Suitable protecting groups for hydroxyl groups are, for example, acyl groups, such as alkanoyl groups, for example acetyl, aroyl groups, for example benzoyl, or arylmethyl groups, for example benzyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or aroyl groups, can be removed by hydrolysis with a suitable base, such as an alkali metal hydroxide, for example lithium, sodium or ammonia. Alternatively, arylmethyl groups, such as benzyl groups, can be removed by hydrogenation, for example, with a catalyst, such as palladium on carbon.
[0120] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or ethyl group which may be removed by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed by treatment with an acid, for example an organic acid, such as trifluoroacetic acid, or for example a benzyl group which may be removed by hydrogenation over a catalyst, such as palladium on carbon.
[0121] Resins may also be used as protecting groups.
[0122] The methodology used to synthesize compounds of formula (I) will vary depending on the nature of HET, X1, X2, X3, X4, R2, R3 and any substituents associated therewith. Suitable processes for their preparation are further described in the accompanying Examples.
[0123] Once a compound of formula (I) has been synthesised by any one of the processes defined herein, the process may then further comprise the following additional steps: (i) removing any protecting groups present; (ii) converting a compound of formula (I) into another compound of formula (I); (iii) forming a pharma- ceutically acceptable salt, hydrate or solvate; and / or (iv) forming a prodrug thereof;
[0124] An example of (ii) above is where a compound of formula (I) is synthesised and then one or more of the groups HET, X1, X2, X3, X4, R2, R3 are further reacted to alter the nature of the groups to provide alternative compounds of formula (I). For example, the compound can be reacted to convert any R group to a substituent other than hydrogen.
[0125] The resulting compound of formula (I) may be isolated and purified using techniques well known in the art.
[0126] biological activity The biological assay described in Example 51 herein can be used to measure the pharmacological effects of the compounds of the present invention.
[0127] The pharmacological properties of compounds of formula I vary with structural changes, but as expected, compounds of the invention were found to be active in the RET assay described in Example 51.
[0128] Generally, compounds of the invention have an IC of 1 μM or less in the RET assay described in Example 51. 50 and preferred compounds of the invention have an IC of 200 nM or less. 50 and most preferred compounds of the invention have an IC of 50 nM or less. 50 Demonstrate the following.
[0129] Preferably, the ratio of RET activity to KDR activity measured in the RET and KDR assays described in Example 51 herein is greater than 5, more preferably greater than 10, even more preferably greater than 25, and most preferably greater than 100.
[0130] In the RET cell assay described herein in Example 51, compounds of formula I suitably have activity of less than 1 μM, with preferred compounds demonstrating activity of 500 nM or less, and most preferred compounds of the invention having an IC of 200 nM or less. 50 Demonstrate the following.
[0131] The following compounds were tested but did not exhibit the desired activity in the assay described in Example 51: 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid; N-Ethyl-6-[1-[(1S,3R)-3-hydroxycyclopentyl]-4-(methylamino)pyrazolo[3,4-d]pyrimidin-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-1H-indole-2-carboxamide; 6-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-[4-amino-1-(2-hydroxyethyl)pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide; 6-[4-amino-1-[2-(dimethylamino)-2-oxo-ethyl]pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide; and 6-[4-amino-1-[3-(dimethylamino)-3-oxo-propyl]pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide
[0132] Pharmaceutical Compositions According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention as defined hereinabove, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, together with a pharma- ceutically acceptable diluent or carrier.
[0133] The compositions of the invention may be in a form suitable for oral use (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as a finely divided powder or liquid aerosol), administration by insufflation (e.g., as a finely divided powder) or parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration, or as a suppository for rectal administration).
[0134] The compositions of the invention can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use can contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.
[0135] An effective amount of a compound of the invention for use in therapy is an amount sufficient to treat or prevent, slow the progression of, and / or reduce the symptoms associated with the proliferative conditions referred to herein.
[0136] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending on the individual being treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain from 0.5 mg to 0.5 g of active agent (more preferably from 0.5 to 100 mg, e.g., 1 to 30 mg), mixed with an appropriate and convenient amount of an excipient, which may vary, for example, from about 5 to about 98 percent by weight of the total composition.
[0137] The magnitude of dosage of the compounds of formula I for therapeutic or prophylactic purposes will of course vary with the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration, in accordance with well-known principles of medicine.
[0138] When using the compounds of the present invention for therapeutic or prophylactic purposes, they are generally administered, for example, in a daily dose in the range of 0.1 mg / kg to 75 mg / kg body weight, given in divided doses as necessary. Generally, lower doses are administered when parenteral routes are used. Thus, for example, for intravenous or intraperitoneal administration, doses in the range of, for example, 0.1 mg / kg to 30 mg / kg body weight are generally used. Similarly, for administration by inhalation, doses in the range of, for example, 0.05 mg / kg to 25 mg / kg body weight are used. Oral administration may also be suitable, particularly in tablet form. Typically, a unit dosage form contains about 0.5 mg to 0.5 g of the compound of the present invention.
[0139] Therapeutic Uses and Applications The present invention provides compounds that function as inhibitors of RET.Furthermore, the compounds of the present invention demonstrate improved selectivity for RET over KDR (i.e., they are potent inhibitors of RET and weak inhibitors of KDR).
[0140] Thus, the present invention provides a method for inhibiting RET kinase enzymatic activity in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0141] The present invention also provides a method for selectively inhibiting RET kinase enzymatic activity relative to KDR enzymatic activity in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0142] The present invention also provides a method of treating a disease or disorder in which RET kinase activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof.
[0143] The present invention provides a method of inhibiting cell proliferation in vitro or in vivo, said method comprising contacting a cell with an effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
[0144] The present invention provides a method of treating a proliferative disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof.
[0145] The present invention provides a method of treating cancer in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof.
[0146] The present invention provides a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.
[0147] The present invention provides a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in the treatment of a proliferative condition.
[0148] The present invention provides a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, for use in the treatment of cancer. In certain embodiments, the cancer is a human cancer.
[0149] The present invention provides a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for use in inhibiting RET kinase enzymatic activity.
[0150] The present invention provides a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for use in the selective inhibition of RET kinase enzymatic activity relative to KDR enzymatic activity.
[0151] The present invention provides a compound as defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of a disease or disorder in which RET kinase enzymatic activity is implicated.
[0152] The invention provides the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of a proliferative condition.
[0153] The invention provides the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of cancer, suitably the medicament is for use in the treatment of cancer in humans.
[0154] The invention provides the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the inhibition of RET kinase enzymatic activity.
[0155] The present invention provides the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the selective inhibition of RET kinase enzymatic activity relative to KDR enzymatic activity.
[0156] The invention provides the use of a compound defined herein, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in the manufacture of a medicament for the treatment of a disease or disorder in which RET kinase activity is implicated.
[0157] The term "proliferative disorder" is used interchangeably herein and relates to unwanted or uncontrolled cell proliferation, whether in vitro or in vivo, of unwanted excess or abnormal cells, such as neoplastic or hyperplastic growth. Examples of proliferative conditions include, but are not limited to, pre-malignant and malignant cell proliferation, including, but not limited to, malignant neoplasms and tumors, cancer, leukemia, psoriasis, bone disease, fibroproliferative disorders (e.g., of connective tissue), and atherosclerosis. Any type of cell may be treated, including, but not limited to, lung, colon, breast, ovary, prostate, liver, pancreas, brain, and skin.
[0158] The anti-proliferative effects of the compounds of the invention have particular application in the treatment of human cancers (by their inhibition of RET kinase enzymatic activity, and / or by selective inhibition of RET kinase enzymatic activity relative to KDR enzymatic activity).
[0159] Anti-cancer effects may occur through one or more mechanisms, including, but not limited to, modulating cell proliferation, inhibiting angiogenesis (the formation of new blood vessels), inhibiting metastasis (the spread of a tumor from its origin), inhibiting invasion (the spread of tumor cells into adjacent normal structures), or promoting apoptosis (programmed cell death).
[0160] In certain embodiments of the invention, the proliferative condition to be treated is cancer, for example medullary thyroid carcinoma (MTC) or non-small cell lung cancer (NSCLC).
[0161] Route of Administration The compounds of the invention or pharmaceutical compositions containing these compounds may be administered to a subject by any convenient route of administration, whether systemic / peripheral or local (ie, to the desired site of action).
[0162] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by patches, plasters, etc.); transmucosal (including, e.g., by patches, plasters, etc.); nasal (e.g., by nasal spray); intraocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via the mouth or nose, e.g., via an aerosol); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, e.g., by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and substernal; e.g., by implantation of a subcutaneous or intramuscular depot or reservoir.
[0163] Combination therapy The antiproliferative treatment defined above may be applied as the sole treatment or may include, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of antitumor agents:- (i) alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan, temozolamide, and nitrosoureas); antimetabolites (e.g., gemcitabine and antifolates, e.g., fluoropyrimidines such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, and hydroxyurea); antitumor antibiotics (e.g., adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, anthracyclines such as idarubicin, mitomycin C, dactinomycin and mithramycin; antimitotic agents (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine and vinorelbine and taxoids such as taxol and taxotere and polo kinase inhibitors); and other antiproliferative / antitumor agents as used in medical oncology such as topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide and teniposide, amsacrine, topotecan and camptothecin) and combinations thereof; (ii) Cytostatics, such as antiestrogens (e.g. tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (e.g. bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or agonists (e.g. goserelin, leuprorelin and buserelin), progestogens (e.g. megestrol acetate), aromatase inhibitors (e.g. anastrozole, letrozole, borazole and exemestane) and inhibitors of 5α-reductase, such as finasteride; (iii) anti-wetting agents [e.g., c-Src kinase family inhibitors, such as 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530; International Patent Application WO01 / 94341), N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl) piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J. Med. Chem., 2004, 47, 6658-6661) and bosutinib (SKI-606), and metalloproteinase inhibitors, such as marimastat, an inhibitor of urokinase plasminogen activator receptor function or antibodies against heparanase]; (iv) Inhibitors of growth factor function: For example, such inhibitors include growth factor antibodies and growth factor receptor antibodies (e.g., the anti-erbB2 antibody trastuzumab [Herceptin®], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibody disclosed by Stern et al. (Critical reviews in oncology / haematology, 2005, Vol. 54, pp 11-29); such inhibitors also include tyrosine kinase inhibitors, such as inhibitors of the epidermal growth factor family (e.g., EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (Gef erlotinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI1033), erbB2 tyrosine kinase inhibitors, e.g. lapatinib; inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; Inhibitors of the platelet-derived growth factor family, such as imatinib and / or nilotinib (AMN107); inhibitors of serine / threonine kinases (e.g., Ras / Raf signaling inhibitors, such as farnesyltransferase inhibitors, e.g., sorafenib (BAY43-9006), tipifarnib (R115777) and lonafarnib (SCH66336)), inhibitors of cell signaling via MEK and / or AKT kinases, c-kinases t inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; Aurora kinase inhibitors (e.g., AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 and AX39459) and cyclin-dependent kinase inhibitors, such as CDK2 and / or CDK4 inhibitors; (v) Anti-angiogenic agents, such as those that inhibit the effects of vascular endothelial growth factor, [e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin™) and, for example, VEGF receptor tyrosine kinase inhibitors, such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW786034) and 4-(4-fluoro-2-methylindole- 5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171; Example 240 in WO00 / 47212), compounds such as those disclosed in International Patent Applications WO97 / 22596, WO97 / 30035, WO97 / 32856 and WO98 / 13354 as well as compounds acting by other mechanisms (e.g. linomide, an inhibitor of integrin αvβ3 function and angiostatin)]; (vi) vascular damaging agents, such as combretastatin A4 and the compounds disclosed in International Patent Applications WO99 / 02166, WO00 / 40529, WO00 / 41669, WO01 / 92224, WO02 / 04434 and WO02 / 08213; (vii) endothelin receptor antagonists, such as zibotentan (ZD4054) or atrasentan; (viii) antisense therapy, e.g., directed to the targets listed above, e.g., ISIS2503, anti-ras antisense; (ix) gene therapy approaches, including approaches that replace abnormal genes, such as abnormal p53 or abnormal BRCA1 or BRCA2, GDEPT (gene-directed enzyme prodrug therapy) approaches, such as those that use cytosine deaminase, thymidine kinase or bacterial nitroreductase enzymes, and approaches that increase a patient's resistance to chemotherapy or radiation therapy, such as multidrug resistance gene therapy; and (x) Immunotherapeutic approaches including, for example, ex vivo and in vivo approaches to increase the immunogenicity of a patient's tumor cells, such as transfection with cytokines, e.g., interleukin 2, interleukin 4 or granulocyte-macrophage colony-stimulating factor, approaches to reduce T cell anergy, approaches using transfected immune cells, e.g., cytokine-transfected dendritic cells, approaches using cytokine-transfected tumor cell lines and approaches using anti-idiotypic antibodies.
[0164] In certain embodiments, the antiproliferative treatment defined above may comprise, in addition to the compound of the invention, conventional surgery or radiation therapy or chemotherapy, which may comprise one or more antitumor agents selected from procarbazine, carmustine, lomustine, irinotecan, temozolomide, cisplatin, carboplatin, methotrexate, etoposide, cyclophosphamide, ifosfamide, and vincristine.
[0165] Such conjoint treatment may be achieved by the simultaneous, sequential or separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within the dosage ranges described above and the other pharma- ceutical active agent(s) within their approved dosage ranges.
[0166] According to this aspect of the invention there is provided a combination comprising a compound of the invention as defined above, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, and another anti-tumour agent for use in the treatment of cancer (e.g. cancer, including solid tumours).
[0167] According to this aspect of the invention there is provided a combination comprising a compound of the invention as defined above, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, and any one of the anti-tumour agents listed above, for use in the treatment of a proliferative condition such as cancer (e.g. cancer, including solid tumours).
[0168] In a further aspect of the present invention, there is provided a compound of the present invention or a pharma- ceutically acceptable salt, hydrate or solvate thereof for use in the treatment of cancer in combination with another anti-tumor agent, any of those listed above.
[0169] In this specification, when the term "combination" is used, it should be understood that it refers to simultaneous, separate or sequential administration.In one aspect of the present invention, "combination" refers to simultaneous administration.In another aspect of the present invention, "combination" refers to separate administration.In a further aspect of the present invention, "combination" refers to sequential administration.When administration is sequential or separate, the delay in administration of the second component should not lose the beneficial effect of the combination.
[0170] According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, in combination with an anti-tumor agent (any selected from those listed above), together with a pharma- ceutically acceptable diluent or carrier. EXAMPLES
[0171] Abbreviation B2(OH)4 tetrahydroxoborate br s broad single line d double line dd Double line double line CDCl3 Chloroform DMAP 4-(Dimethylamino)pyridine DCM Dichloromethane (methylene chloride) DIPEA N,N,-Diisopropylamine, Hunig's base DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide. EDCI.HCl 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride EtBr Ethyl bromide (bromoethane) EtOAc Ethyl acetate EtOH Ethanol (Ethyl Alcohol) HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) HCl Hydrochloric acid HPLC High Performance Liquid Chromatography Hz Hertz J coupling constant K2CO3 Potassium Carbonate KOAc Potassium Acetate LCMS Liquid Chromatography-Mass Spectrometry LiOH.H2O Lithium hydroxide monohydrate m multiplet MeOH Methanol (Methyl Alcohol) MgSO4 Magnesium Sulfate MHz Megahertz N2 Nitrogen NaHCO3 Sodium Bicarbonate Na2SO4 Sodium Sulfate NH4Cl Ammonium chloride NMR nuclear magnetic resonance POCl3 Phosphorus oxychloride q quartet s single line t triple line tt Triple line of triple lines THF Tetrahydrofuran XPhos 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl XPhos-Pd-G2 Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)
[0172] method General Experiment Flash chromatography was performed using pre-packed silica gel cartridges. Merck Type 60 F 254Thin-layer chromatography was performed using 5 x 10 cm plates coated with 0.25 mm thick silica gel. All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from Sigma-Aldrich Chemical Company Ltd. or Fisher Chemicals Ltd. and used without further drying. HPLC grade solvents were obtained from Fisher Chemicals Ltd.
[0173] Unless otherwise indicated, all compounds were analyzed by LC-MS and 1 The purity was >90% as determined by examination of both H NMR spectra. When Cl or Br were present, the expected isotope distribution patterns were observed.
[0174] NMR proton( 1 H NMR spectra were recorded on 300 MHz or 400 MHz Bruker spectrometers. Solutions were typically prepared in either deuterated chloroform (CDCl3) or deuterated dimethylsulfoxide (DMSO-d6) with chemical shifts referenced to tetramethylsilane (TMS) or deuterated solvents as internal standards. 1 H NMR data are reported as chemical shifts (δ), integrals (e.g., 1 H), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublets, etc.) and coupling constant (J) in Hz (app means apparent coupling of broad signals). Deuterated solvents were obtained from Sigma-Aldrich Chemical Company, Goss or Fluorochem.
[0175] LCMS method AnalyticalLC-MS LC-MS analyses were performed on a Waters Acquity UPLC system equipped with a BEH C18 1.7 μM column (2.1 × 50 mm or 2.1 × 100 mm) and UV diode array detection (210-400 nm). Positive and negative mass ion detection was performed using a Waters SQD detector. Analyses were performed in either buffered acidic or basic solvents and gradients as detailed below. Low pH: Solvent A - Water + 10 mM ammonium formate + 0.1% formic acid Solvent B – Acetonitrile + 5% water + 0.1% formic acid High pH: Solvent A - Water + 10 mM ammonium bicarbonate + 0.1% ammonia solution Solvent B – Acetonitrile + 0.1% ammonia solution gradient: [Table 1]
[0176] Preparative HPLC Some compounds were purified by preparative HPLC on a Waters FractionLynx MS automated purification system with a Waters XBridge 5 μm C18, 100 mm × 19 mm id column operated at a flow rate of 20 mL / min with UV diode array detection (210-400 nm) and mass-directed collection using both positive and negative mass ion detection.
[0177] Purification was performed using buffered acidic or basic solvent systems as appropriate. Compound retention times on the system were routinely assessed using test injections of 30-50 μL and standard gradients, and then purified using appropriately selected focusing gradients based on the observed retention times, as detailed below. Low pH: Solvent A - Water + 10 mM ammonium formate + 0.1% formic acid Solvent B – Acetonitrile + 5% water + 0.1% formic acid High pH: Solvent A - Water + 10 mM ammonium formate + 0.1% ammonia solution Solvent B – Acetonitrile + 5% water + 0.1% ammonia solution Standard gradient: [Table 2] Convergence gradient: [Table 3]
[0178] Synthesis method Several methods for the chemical synthesis of the compounds of the present invention are described herein. These and / or other well-known methods can be modified and / or adapted in known ways to facilitate the synthesis of additional compounds within the scope of the present invention. Intermediates 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid [ka]
[0179] A mixture of 6-chloro-1H-indole-2-carboxylic acid (1.92 g, 9.8 mmol), XPhos-Pd-G2 (155 mg, 0.2 mmol), XPhos (187 mg, 0.4 mmol), B2(OH)4 (2.59 g, 29.5 mmol) and KOAc (2.89 g, 29.5 mmol) in EtOH (80 ml) was heated at 80° C. under N2 for 2 h. A solution of K2CO3 (4.07 g, 29.8 mmol) in water (20 ml) and a solution of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.96 g, 7.3 mmol) in 1,4-dioxane (25 ml) were added and the mixture was heated at 80° C. for 15 h. The reaction was cooled to room temperature, concentrated under reduced pressure to remove organics, then acidified to pH 5 with 1 M aqueous HCl to produce a solid which was collected by filtration, washed with water, and dried under vacuum at 50° C. to yield 6-(4-amino-1-(t-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid (2.92 g, 85%) as an off-white solid.
[0180] LCMS: [M+H] + 351.2 1 H NMR: (300 MHz, DMSO-d6) δ 11.91 (s, 1H), 8.25 (s, 1H), 7.80 (d, J=8.29 Hz, 1H), 7.71 (s, 1H), 7.37 (dd, J=1.32, 8.10 Hz, 1H), 7.17 (d, J=1.51 Hz, 1H), 6.51 (s, 2H), 1.77 (s, 9H).
[0181] 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-chloro-1H-indole-2-carboxylic acid [ka] To a solution of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid (793 mg, 2.3 mmol) in DMF (10 mL) was added N-chlorosuccinimide (302.23 mg, 2.3 mmol) at room temperature. The reaction was stirred for 18 hours and then diluted with water (50 ml). The resulting suspension was stirred for 10 minutes, filtered, washed with water and dried in vacuo to yield 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-chloro-1H-indole-2-carboxylic acid (518 mg, 1.3 mmol, 60%) as a purple solid. The material was used without further purification.
[0182] LCMS: 58% purity, [MH]-383.2.
[0183] 1 H NMR (300 MHz, DMSO-d6) δ 12.18 (s, 1H), 8.27 (s, 1H), 7.69-7.80 (m, 2H), 7.48 (dd, J=1.41, 8.38 Hz, 1H), 1.77 (s, 9H).
[0184] 6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid [ka] Prepared as described for 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid using 3-bromo-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine instead of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine to yield (2.88 g, 86%) as an off-white solid.
[0185] LCMS: [M+H] + 337.2.
[0186] 6-Bromo-N-methyl-1H-indole-2-carboxamide [ka] To a solution of 6-bromo-1H-indole-2-carboxylic acid (1.0 g, 4.2 mmol) in DMF (25 ml) was added DIPEA (1.7 ml, 10.0 mmol), methylamine hydrochloride (338 mg, 5.0 mmol) and HATU (1.9 g, 5.0 mmol). The mixture was stirred at room temperature for 18 h and then partitioned between water and EtOAc. The organic layer was separated, washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (40 g column, 0-100% EtOAc in isohexane) to give 6-bromo-N-methyl-1H-indole-2-carboxamide (657 mg, 63%) as a brown solid.
[0187] LCMS: [M+H] + 253.0 / 254.9
[0188] 1 H NMR: (400 MHz, DMSO-d6) δ 11.71 (br s, 1H), 8.52 (q, J=4.09 Hz, 1H), 7.59 (d, J=6.55 Hz, 2H), 7.58 (s, 1H), 7.13-7.18 (m, 1H), 7.08 (s, 1H), 2.81 (d, J=4.64 Hz, 3H).
[0189] 6-Bromo-N-cyclopropyl-1H-indole-2-carboxamide [ka] Prepared as described for 6-bromo-N-methyl-1H-indole-2-carboxamide using cyclopropylamine instead of methylamine hydrochloride to yield (181 mg, 62%) as a white solid.
[0190] LCMS: [M+H] + 278.9 / 280.9.
[0191] 6-Bromo-N-ethyl-1H-indole-2-carboxamide [ka] Prepared as described for 6-bromo-N-methyl-1H-indole-2-carboxamide using ethylamine instead of methylamine hydrochloride to yield (144 mg, 52%) as a white solid.
[0192] LCMS: [M+H] + 266.9 / 268.9.
[0193] 1 H NMR: (400 MHz, CHLOROFORM-d) δ 9.51 (br s, 1H), 7.61 (s, 1H), 7.50 (d, J=8.54 Hz, 1H), 7.24 (dd, J=1.71, 8.54 Hz, 1H), 6.77 (dd, J=0.70, 2.04 Hz, 1H), 6.13 (br s, 1H), 3.55 (dq, J=5.89, 7.23 Hz, 2H), 1.30 (t, J=7.29 Hz, 3H).
[0194] 6-Bromo-N-cyclobutyl-1H-indole-2-carboxamide [ka] Prepared as described for 6-bromo-N-methyl-1H-indole-2-carboxamide using cyclobutylamine instead of methylamine hydrochloride to yield (268 mg, 73%) as a beige solid.
[0195] LCMS: [M+H]+293.1 / 295.1.
[0196] 1 H NMR (400 MHz, DMSO-d6) δ 11.66 (s, 1H), 8.67 (d, J=7.75 Hz, 1H), 7.58 (s, 1H), 7.59 (d, J=8.94 Hz, 1H), 7.11-7.19 (m, 2H), 4.44 (sxt, J=8.17 Hz, 1H), 2.17-2.30 (m, 2H), 2.01-2.14 (m, 2H), 1.60-1.77 (m, 2H).
[0197] 6-Bromo-N-methoxy-1H-indole-2-carboxamide [ka] Prepared as described for 6-bromo-N-methyl-1H-indole-2-carboxamide using O-methylhydroxylamine hydrochloride instead of methylamine hydrochloride to yield (300 mg, 89%) as an off-white solid.
[0198] LCMS: [M+H] + 269.0 / 271.0.
[0199] 6-Bromo-3-fluoro-N-methyl-1H-indole-2-carboxamide [ka] Step 1: To a suspension of ethyl 6-bromo-1H-indole-2-carboxylate (688 mg, 2.6 mmol) in acetonitrile (30 mL) was added saturated aqueous NaHCO3 (5.6 ml). The mixture was cooled on ice before Selectfluor™ (1 g, 2.8 mmol) was added portionwise. The solution was allowed to warm to room temperature and then heated at 80° C. for 4 h. The solution was allowed to cool to room temperature before a further charge of Selectfluor (1 g, 2.8 mmol) was added and heated at 80° C. for 1 h. The mixture was allowed to cool to room temperature and then extracted with ethyl acetate (×3). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography (0-50% ethyl acetate in cyclohexane) to yield ethyl 6-bromo-3-fluoro-1H-indole-2-carboxylate (362 mg) as a pale yellow solid. The product was not pure but was used in the next step.
[0200] Step 2: To a solution of ethyl 6-bromo-3-fluoro-1H-indole-2-carboxylate (362 mg) in THF (10 mL) was added a solution of LiOH.H2O (213 mg, 5.1 mmol) in water (6.4 mL). The mixture was stirred at room temperature for 3 h. An additional charge of LiOH.H2O (213 mg, 5.1 mmol) in water (6.4 mL) was added and the mixture was heated at 60° C. for 2 h. The mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was acidified with 1 M aqueous HCl and extracted with EtOAc (×3). The combined organic phases were dried over Na2SO4 and evaporated under reduced pressure to give 6-bromo-3-fluoro-1H-indole-2-carboxylic acid (322 mg) as a pale yellow solid. The impure product was used without further purification.
[0201] Step 3: The impure acid (322 mg) was subjected to the amide coupling conditions described for 6-bromo-N-methyl-1H-indole-2-carboxamide to yield 6-bromo-3-fluoro-N-methyl-1H-indole-2-carboxamide (52 mg, 7% over three steps) as a pale yellow solid. The material was not pure but was carried forward.
[0202] 6-Bromo-N,3-dimethyl-1H-indole-2-carboxamide [ka] Step 1: To a solution of 6-bromo-N-methyl-1H-indole-2-carboxamide (2.3 g, 9.1 mmol) in DMF (10 mL) was added POCl3 (1.67 g, 10.9 mmol) at 0 °C. The mixture was stirred at room temperature for 15 min and then at 100 °C for 5 h. The mixture was poured into ice water (100 mL) and the product was extracted with EtOAc (4 x 100 mL). The combined organic phase was washed with brine (100 mL), dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography to produce 6-bromo-3-formyl-N-methyl-1H-indole-2-carboxamide (2.1 g). The material was impure but was carried on to the next step.
[0203] Step 2: To a solution of 6-bromo-3-formyl-N-methyl-1H-indole-2-carboxamide (2.1 g) in trifluoroacetic acid (15 mL) was added triethylsilane (608 mg, 5.2 mmol) at 0° C. The mixture was stirred at room temperature for 18 h, then poured into saturated aqueous Na2CO3 (100 ml) and extracted with EtOAc (5×100 ml). The combined organic phases were washed with brine (100 mL), dried over MgSO4, and concentrated under reduced pressure. The residue was purified by flash column chromatography to give 6-bromo-N,3-dimethyl-1H-indole-2-carboxamide (388 mg, 16% over two steps). The material was not pure but was carried forward.
[0204] 6-Bromo-N-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-indole-2-carboxamide [ka] To a solution of 1,3-dimethyl-1H-pyrazol-5-amine (86 mg, 0.8 mmol) in pyridine (5 ml) was added 6-bromo-1H-indole-2-carbonyl chloride (200 mg, 0.8 mmol). The mixture was stirred at room temperature for 2 h and then concentrated under reduced pressure. The residue was diluted with saturated aqueous NaHCO3 and then extracted with EtOAc (3 x 20 ml). The combined organic phases were concentrated under reduced pressure. The residue was purified by flash column chromatography (1:1 EtOAc:petroleum ether) to yield 6-bromo-N-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-indole-2-carboxamide (50 mg, 19%).
[0205] LCMS: [M+H] + 333.0 / 335.0.
[0206] 3-Bromo-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [ka] A mixture of 3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1 g, 4.7 mmol) and K2CO3 (1.29 g, 9.3 mmol) in DMF (10 mL) was heated at 60° C. under nitrogen for 30 min. The solution was cooled to room temperature and then EtBr (0.42 mL, 5.6 mmol) was added. The mixture was heated at 60° C. under nitrogen for 4 h, then cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between water and EtOAc. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to give the crude product (980 mg, 87%) as a yellow solid, which was used directly in the next step without further purification.
[0207] LCMS: [M+H] + 242.0 / 244.0.
[0208] 3-Bromo-1-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [ka] To a solution of 3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.2 g, 5 mmol) in 1,2-dichloroethane (50 mL) was added cyclopropylboronic acid (860 mg, 10 mmol), copper(II) acetate (908 mg, 5 mmol), 2,2'-bipyridine (780 mg, 5 mmol) and NaHCO3 (1.1 g, 10 mmol). The mixture was stirred at 70 °C under air for 2 h and then cooled to room temperature. The reaction mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with dichloromethane (3 x 50 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (0 to 100% EtOAc in isohexane) to afford 3-bromo-1-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (121 mg, 9%) as a white solid.
[0209] LCMS: [M+H] + 254.0 / 256.0.
[0210] 1 H NMR (400 MHz, CHLOROFORM-d) δ 8.38 (s, 1H), 5.89 (br s, 2H), 3.73 (tt, J=3.71, 7.28 Hz, 1H), 1.27-1.34 (m, 2H), 1.12-1.19 (m, 2H).
[0211] final compound Example 1 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide [ka] To a mixture of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid (50 mg, 0.14 mmol) and HATU (65 mg, 0.17 mmol) in DMF (1 ml) was added DIPEA (0.07 ml, 0.42 mmol). The mixture was stirred for 5 min before adding 2-aminothiazole (17 mg, 0.17 mmol). The mixture was stirred at room temperature for 18 h, then diluted with water and extracted with EtOAc (3x). The combined extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC to yield 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide (14 mg, 0.03 mmol, 23%) as a yellow solid.
[0212] LCMS: Purity >95%, [M+H] + 433.1.
[0213] 1 H NMR (400 MHz, DMSO-d6) δ 12.04 (br s, 1H), 8.36 (s, 1H), 8.25 (s, 1H), 7.84 (d, J=7.89 Hz, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.57 (d, J=3.55 Hz, 1H), 7.39 (dd, J=1.47, 8.25 Hz, 1H), 7.27 (d, J=3.61 Hz, 1H), 1.78 (s, 9H).
[0214] Example 2 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-butyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using n-butylamine instead of 2-aminothiazole to yield (26 mg, 51%) as a white solid.
[0215] LCMS: Purity >95%, [M+H] + 406.2.
[0216] 1 H NMR (400 MHz, DMSO-d6) δ 11.66-11.76 (m, 1H), 8.50 (t, J=5.72 Hz, 1H), 8.24 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.33 (dd, J=1.47, 8.25 Hz, 1H), 7.19 (d, J=1.28 Hz, 1H), 3.30 (br s, 2H), 1.77 (s, 9H), 1.54 (quin, J=7.20 Hz, 2H), 1.36 (sxt, J=7.70 Hz, 2H), 0.93 (t, J=7.34 Hz, 3H).
[0217] Example 3 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methoxyethyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 2-methoxyethylamine instead of 2-aminothiazole to yield (30 mg, 53%) as a white solid.
[0218] LCMS: Purity >95%, [M+H] + 408.2.
[0219] 1H NMR (400 MHz, DMSO-d6) δ 11.65-11.82 (m, 1H), 8.53-8.66 (m, 1H), 8.24 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, J=1.47, 8.25 Hz, 1H), 7.21 (d, J=1.34 Hz, 1H), 3.43-3.55 (m, 5H), 3.30 (s, 2H), 1.77 (s, 9H).
[0220] Example 4 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-propyl-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using n-propylamine instead of 2-aminothiazole to yield (33 mg, 60%) as a white solid.
[0221] LCMS: Purity >95%, [M+H] + 392.2.
[0222] 1 H NMR (400 MHz, DMSO-d6) δ 11.70-11.74 (m, 1H), 8.53 (t, J=5.72 Hz, 1H), 8.24 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.33 (dd, J=1.50, 8.22 Hz, 1H), 7.19 (s, 1H), 3.24-3.27 (m, 2H), 1.77 (s, 9H), 1.57 (sxt, J=7.34 Hz, 2H), 0.92 (t, J=7.40 Hz, 3H)
[0223] Example 5 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methoxy-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using O-methylhydroxylamine hydrochloride instead of 2-aminothiazole to yield (51 mg, 47%) as a white solid.
[0224] LCMS: Purity >95%, [M+H] + 380.2.
[0225] 1 H NMR (400 MHz, DMSO-d6) δ 11.84 (br s, 1H), 8.24 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, J=1.44, 8.22 Hz, 1H), 7.06 (s, 1H), 3.76 (s, 3H), 1.77 (s, 9H)
[0226] Example 6 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-fluoroethyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 2-fluoroethylamine hydrochloride instead of 2-aminothiazole to yield (32 mg, 28%) as a white solid.
[0227] LCMS: Purity >95%, [M+H] + 396.3.
[0228] 1H NMR (300 MHz, DMSO-d6) δ 11.80 (br s, 1H), 8.82 (br t, J=5.04 Hz, 1H), 8.25 (s, 1H), 7.79 (br d, J=8.19 Hz, 1H), 7.71 (s, 1H), 7.35 (br d, J=8.01Hz, 1H), 7.25 (s, 1H), 4.66 (br t, J=4.76 Hz, 1H), 4.50 (br t, J=4.66 Hz, 1H), 3.66 (br d, J=4.80 Hz, 1H), 3.57 (br d, J=4.80 Hz, 1H), 1.77 (s, 9H)
[0229] Example 7 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isobutyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using isobutylamine instead of 2-aminothiazole to yield (51 mg, 43%) as a white solid.
[0230] LCMS: Purity >95%, [M+H] + 406.3.
[0231] 1 H NMR (400 MHz, DMSO-d6) δ 11.72-11.82 (m, 1H), 8.56 (t, J=5.93 Hz, 1H), 8.31 (s, 1H), 7.79 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.34 (dd, J=1.53, 8.25 Hz, 1H), 7.23 (d, J=1.34 Hz, 1H), 3.13 (t, J=6.67 Hz, 2H), 1.87 (spt, J=7.09 Hz, 1H), 1.77 (s, 9H), 0.92 (d, J=6.66 Hz, 6H)
[0232] Example 8 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-benzyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using benzylamine instead of 2-aminothiazole to yield (34 mg, 32%) as a white solid.
[0233] LCMS: Purity >95%, [M+H] + 440.3.
[0234] 1 H NMR (400 MHz, DMSO-d6) δ 11.75-11.85 (m, 1H), 9.13 (t, J=6.08 Hz, 1H), 8.25 (s, 1H), 7.79 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.24-7.38 (m, 7H), 4.54 (d, J=6.05 Hz, 2H), 1.77 (s, 9H)
[0235] Example 9 - 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-phenethyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using phenethylamine instead of 2-aminothiazole to yield (39 mg, 36%) as a white solid.
[0236] LCMS: Purity >95%, [M+H] + 454.3.
[0237] 1H NMR (400 MHz, DMSO-d6) δ 11.72-11.81 (m, 1H), 8.68 (t, J=5.69 Hz, 1H), 8.32 (s, 1H), 7.79 (d, J=8.31 Hz, 1H), 7.69 (s, 1H), 7.25-7.36 (m, 5H), 7.17-7.25 (m, 2H), 3.49-3.57 (m, 2H), 2.89 (t, J=7.37 Hz, 2H), 1.77 (s, 9H)
[0238] Example 10 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(cyclopropylmethyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using cyclopropylmethanamine instead of 2-aminothiazole to yield (64 mg, 55%) as a beige solid.
[0239] LCMS: Purity >95%, [M+H] + 404.2.
[0240] 1 H NMR (400 MHz, DMSO-d6) δ 11.73 (s, 1H), 8.63 (t, J=5.78 Hz, 1H), 8.24 (s, 1H), 7.78 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.34 (dd, J=1.47, 8.25 Hz, 1H), 7.22 (d, J=1.22 Hz, 1H), 3.19 (t, J=6.27 Hz, 2H), 1.77 (s, 9H), 1.06 (s, 1H), 0.43-0.50 (m, 2H), 0.23-0.30 (m, 2H)
[0241] Example 11 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using 2,2,2-trifluoroethan-1-amine instead of 2-aminothiazole to yield (68 mg, 54%) as a beige solid.
[0242] LCMS: Purity >95%, [M+H] + 432.2.
[0243] 1 H NMR (400 MHz, DMSO-d6) δ 11.85-11.95 (m, 1H), 9.17 (t, J=6.39 Hz, 1H), 8.32 (s, 1H), 7.82 (d, J=8.31 Hz, 1H), 7.71 (s, 1H), 7.37 (dt, J=1.59, 8.00 Hz, 1H), 7.33-7.35 (m, 1H), 4.09-4.20 (m, 2H), 1.78 (s, 9H).
[0244] Example 12 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,2-difluoroethyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 2,2-difluoroethan-1-amine instead of 2-aminothiazole to yield (41 mg, 34%) as a yellow solid.
[0245] LCMS: Purity >95%, [M+H] + 414.2.
[0246] 1H NMR (400 MHz, DMSO-d6) δ 11.77-11.88 (m, 1H), 8.93 (t, J=5.99 Hz, 1H), 8.25 (s, 1H), 7.80 (d, J=8.25 Hz, 1H), 7.71 (s, 1H), 7.36 (dd, J=1.47, 8.25 Hz, 1H), 7.28 (d, J=1.34 Hz, 1H), 6.16 (tt, J=3.91, 55.80 Hz, 1H), 3.63-3.93 (m, 2H), 1.77 (s, 9H).
[0247] Example 13 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethoxy-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using O-ethylhydroxylamine hydrochloride instead of 2-aminothiazole to yield (56 mg, 49%) as a yellow solid.
[0248] LCMS: Purity >95%, [M+H] + 394.2.
[0249] 1 H NMR (400 MHz, DMSO-d6) δ 11.85 (br s, 1H), 11.75 (br s, 1H), 8.24 (s, 1H), 7.78 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.35 (dd, J=1.47, 8.25 Hz, 1H), 7.10 (s, 1H), 3.98 (q, J=7.00 Hz, 2H), 1.77 (s, 9H), 1.25 (t, J=7.00 Hz, 3H).
[0250] Example 14 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(cyclopropylmethoxy)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using O-(cyclopropylmethyl)hydroxylamine hydrochloride instead of 2-aminothiazole to yield (68 mg, 56%) as a yellow solid.
[0251] LCMS: Purity >95%, [M+H] + 420.2.
[0252] 1 H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 11.77 (br s, 1H), 8.28 (s, 1H), 7.78 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.35 (dd, J=1.44, 8.28 Hz, 1H), 7.10 (s, 1H), 3.76 (d, J=7.15 Hz, 2H), 1.77 (s, 9H), 1.14 (ddd, J=2.90, 4.65, 7.79 Hz, 1H), 0.52-0.60 (m, 2H), 0.25-0.34 (m, 2H).
[0253] Example 15 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using 1,3,4-thiadiazol-2-amine instead of 2-aminothiazole to yield (22 mg, 18%) as a yellow solid.
[0254] LCMS: Purity 90~95%, [M+H] + 434.2.
[0255] 1H NMR (400 MHz, DMSO-d6) δ 12.04 (br s, 1H), 9.16 (s, 1H), 8.25 (s, 1H), 8.17 (s, 1H), 7.85 (d, J=8.31 Hz, 1H), 7.75 (s, 1H), 7.69 (s, 1H), 7.39 (dd, J=1.44, 8.28 Hz, 1H), 1.78 (s, 9H).
[0256] Example 16 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-methylpyrazol-3-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 1-methyl-1H-pyrazol-3-amine instead of 2-aminothiazole to yield (46 mg, 37%) as a white solid.
[0257] LCMS: Purity >95%, [M+H] + 430.3.
[0258] 1 H NMR (400 MHz, DMSO-d6) δ 11.80-11.89 (m, 1H), 10.95 (s, 1H), 8.26 (s, 1H), 7.80 (d, J=8.25 Hz, 1H), 7.73 (s, 1H), 7.60-7.66 (m, 1H), 7.56 (d, J=1.34 Hz, 1H), 7.36 (dd, J=1.50, 8.22 Hz, 1H), 6.63 (d, J=2.20 Hz, 1H), 3.79-3.83 (m, 3H), 1.78 (s, 9H).
[0259] Example 17 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methoxyethoxy)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using O-(2-methoxyethyl)hydroxylamine instead of 2-aminothiazole to yield (31 mg, 25%) as a white solid.
[0260] LCMS: Purity 90~95%, [M+H] + 424.3.
[0261] 1 H NMR (400 MHz, DMSO-d6) δ 11.86 (br s, 2H), 8.24 (s, 1H), 7.78 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.35 (dd, J=1.47, 8.25 Hz, 1H), 7.12 (br s, 1H), 4.02-4.11 (m, 2H), 3.49-3.66 (m, J=3.70, 5.30 Hz, 2H), 3.31 (br s, 3H), 1.77 (s, 9H).
[0262] Example 18 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methylpyrazol-3-yl)-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using 1-methyl-1H-pyrazol-5-amine instead of 2-aminothiazole to yield (25 mg, 20%) as a beige solid.
[0263] LCMS: Purity 90~95%, [M+H] + 430.3.
[0264] 1H NMR (400 MHz, DMSO-d6) δ 12.02 (br s, 1H), 10.42 (br s, 1H), 8.25 (s, 1H), 7.85 (d, J=8.25 Hz, 1H), 7.66-7.79 (m, 1H), 7.47 (br s, 1H), 7.43 (d, J=1.90 Hz, 1H), 7.39 (dd, J=1.47, 8.25 Hz, 1H), 6.28 (d, J=1.96 Hz, 1H), 3.74 (s, 3H), 1.75-1.80 (m, 9H).
[0265] Example 19 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-phenyl-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using aniline instead of 2-aminothiazole to yield (30 mg, 24%) as a beige solid.
[0266] LCMS: Purity >95%, [M+H] + 426.2.
[0267] 1 H NMR (400 MHz, DMSO-d6) δ 11.89-11.98 (m, 1H), 10.28 (s, 1H), 8.29 (s, 1H), 7.83-7.90 (m, 2H), 7.82 (d, J=0.92 Hz, 1H), 7.74 (s, 1H), 7.52 (d, J=1.41 Hz, 1H), 7.32-7.46 (m, 3H), 7.13 (tt, J=0.90, 7.20 Hz, 1H), 1.78 (s, 9H).
[0268] Example 20 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-hydroxyethyl)-1H-indole-2-carboxamide [ka] To a mixture of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid (100 mg, 0.28 mmol) and PyBOP (148 mg, 0.28 mmol) in DMF (2 ml) was added triethylamine (0.12 ml, 0.84 mmol) and ethanolamine (17 μL, 0.17 mmol). The mixture was stirred at room temperature for 18 h, then diluted with water and extracted with EtOAc (3×). The combined extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (10% MeOH in DCM) to give 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-hydroxyethyl)-1H-indole-2-carboxamide (32 mg, 0.08 mmol, 28%) as a beige solid.
[0269] LCMS: Purity >95%, [M+H] + 394.4.
[0270] 1 H NMR (400 MHz, DMSO-d6) δ 11.66-11.80 (m, 1H), 8.53 (t, J=5.90 Hz, 1H), 8.24 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.33 (dd, J=1.47, 8.19 Hz, 1H), 7.13-7.26 (m, 1H), 4.78 (s, 1H), 3.55 (q, J=5.80 Hz, 2H), 3.37 (q, J=5.80 Hz, 2H), 1.77 (s, 9H).
[0271] Example 21 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 5-methyl-1,3,4-thiadiazol-2-amine instead of 2-aminothiazole to yield (9 mg, 7%) as a white solid.
[0272] LCMS: Purity >95%, [M+H] + 448.3.
[0273] 1 H NMR (400 MHz, DMSO-d6) δ 12.05 (br s, 1H), 8.25 (s, 1H), 8.19 (s, 1H), 7.84 (d, J=8.25 Hz, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.39 (dd, J=1.44, 8.28 Hz, 1H), 2.64 (s, 3H), 1.78 (s, 9H).
[0274] Example 22 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-2-carboxamide [ka] To a suspension of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid (175 mg, 0.5 mmol) in DCM (5 mL) was added oxalyl chloride (51 μL, 0.6 mmol) and a drop of DMF. The mixture was stirred at room temperature for 1 h then concentrated under reduced pressure and azeotroped with toluene to give a yellow solid. This was redissolved in DCM (5 ml) before adding 1,2,4-thiadiazol-5-amine (56 mg, 0.5 mmol), DIPEA (0.1 ml, 0.6 mmol) and DMAP (3 mg, 5 mol%). The reaction was stirred at room temperature for 24 h then concentrated under reduced pressure. The residue was partitioned between EtOAc and water then filtered to remove solids. The organic phase was separated and washed with saturated NaHCO3 and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (0-100% EtOAc in isohexane) to give the crude product, which was further purified by preparative HPLC to give 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-2-carboxamide (16 mg, 0.03 mmol, 7%) as a white solid.
[0275] LCMS: Purity 90~95%, [M+H] + 434.2.
[0276] 1 H NMR (400 MHz, DMSO-d6) δ 12.10 (br s, 1H), 8.48 (s, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 7.85 (d, J=8.25 Hz, 1H), 7.75 (s, 1H), 7.67 (br s, 1H), 7.40 (dd, J=1.41, 8.31 Hz, 1H), 1.75-1.82 (m, 9H).
[0277] Example 23 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-thienyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 3-aminothiophene oxalate instead of 2-aminothiazole to yield (45 mg, 36%) as a white solid.
[0278] LCMS: Purity >95%, [M+H] + 432.2.
[0279] 1 H NMR (400 MHz, DMSO-d6) δ 11.90-12.01 (m, 1H), 10.80 (s, 1H), 8.25 (s, 1H), 7.84 (d, J=8.25 Hz, 1H), 7.71-7.77 (m, 2H), 7.52 (dd, J=3.21, 5.17 Hz, 1H), 7.45 (d, J=1.34 Hz, 1H), 7.34-7.41 (m, 2H), 1.78 (s, 9H).
[0280] Example 24 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-5-yl-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using thiazol-5-amine instead of 2-aminothiazole to yield (14 mg, 11%) as a white solid.
[0281] LCMS: Purity >95%, [M+H] + 433.2.
[0282] 1H NMR (400 MHz, DMSO-d6) δ 12.07 (br s, 1H), 11.74-12.01 (m, 1H), 8.65 (d, J=0.73 Hz, 1H), 8.21-8.28 (m, 1H), 7.88 (d, J=8.46 Hz, 1H), 7.83 (s, 1H), 7.75 (s, 1H), 7.50 (s, 1H), 7.40 (dd, J=1.44, 8.28 Hz, 1H), 1.73-1.83 (m, 9H).
[0283] Example 25 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isoxazol-4-yl-1H-indole-2-carboxamide [ka] A mixture of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid (100 mg, 0.28 mmol), EDCI.HCl (109 mg, 0.57 mmol) and HOBt.H2O (87 mg, 0.57 mmol) in DMF (4 ml) was stirred at room temperature for 1 h before isoxazol-4-amine (34 mg, 0.28 mmol) was added. After 1 h, DIPEA (0.14 ml, 0.86 mmol) was added and the mixture was stirred for 3 h. Additional DIPEA (0.1 ml, 0.6 mmol) was added and the reaction was stirred at room temperature for 18 h then concentrated under reduced pressure. The residue was partitioned between DCM and water, separated and the organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (0-5% MeOH in DCM) to give the crude product, which was further purified by preparative HPLC to give 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isoxazol-4-yl-1H-indole-2-carboxamide (7 mg, 0.02 mmol, 6%) as a white solid.
[0284] LCMS: Purity >95%, [M+H]+ 417.2.
[0285] 1 H NMR (400 MHz, DMSO-d6) δ 12.01 (s, 1H), 10.88 (s, 1H), 9.28 (s, 1H), 8.78 (s, 1H), 8.25 (s, 1H), 7.86 (d, J=8.31 Hz, 1H), 7.75 (s, 1H), 7.40 (d, J=1.47 Hz, 1H), 7.38-7.39 (m, 1H), 1.78 (s, 9H)
[0286] Example 26 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-methylthiazol-2-yl)-1H-indole-2-carboxamide [ka] Prepared as described for example 1 using 4-methylthiazol-2-amine instead of 2-aminothiazole to yield (5 mg, 1%) as a beige solid.
[0287] LCMS: Purity >95%, [M+H] + 447.2.
[0288] 1 H NMR (400 MHz, DMSO-d6) δ 12.70 (br s, 1H), 12.02 (br s, 1H), 8.25 (s, 1H), 7.83 (d, J=8.01 Hz, 1H), 7.74 (s, 1H), 7.69 (s, 1H), 7.39 (dd, J=1.44, 8.28 Hz, 1H), 6.82 (s, 1H), 2.33 (d, J=0.92 Hz, 3H), 1.78 (s, 9H).
[0289] Example 27 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-ethylpyrazol-3-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 1-ethyl-1H-pyrazol-3-amine instead of 2-aminothiazole to yield (26 mg, 20%) as an off-white solid.
[0290] LCMS: Purity >95%, [M+H] + 444.3.
[0291] 1 H NMR (400 MHz, DMSO-d6) δ 11.77-11.90 (m, 1H), 10.98 (s, 1H), 8.25 (s, 1H), 7.79 (d, J=8.31 Hz, 1H), 7.72 (s, 1H), 7.68 (s, 1H), 7.57 (d, J=1.28 Hz, 1H), 7.36 (dd, J=1.50, 8.22 Hz, 1H), 6.63 (d, J=2.26 Hz, 1H), 4.10 (q, J=7.25 Hz, 2H), 1.77 (s, 9H), 1.40 (t, J=7.24 Hz, 3H).
[0292] Example 28 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-methoxyethyl)pyrazol-3-yl]-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 1-(2-methoxyethyl)-1H-pyrazol-3-amine instead of 2-aminothiazole to yield (29 mg, 21%) as a white solid.
[0293] LCMS: Purity >95%, [M+H] + 474.3.
[0294] 1 H NMR (400 MHz, DMSO-d6) δ 11.81-11.88 (m, 1H), 10.99 (s, 1H), 8.22-8.26 (m, 1H), 7.79 (d, J=8.25 Hz, 1H), 7.72 (s, 1H), 7.66 (d, J=2.26 Hz, 1H), 7.57 (d, J=1.28 Hz, 1H), 7.36 (dd, J=1.47, 8.25 Hz, 1H), 6.64 (d, J=2.26 Hz, 1H), 4.22 (t, J=5.32 Hz, 2H), 3.70 (t, J=5.32 Hz, 2H), 3.25 (s, 3H), 1.77 (s, 9H).
[0295] Example 29 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-fluoroethyl)pyrazol-3-yl]-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 1-(2-fluoroethyl)-1H-pyrazol-3-amine instead of 2-aminothiazole to yield (32 mg, 24%) as a white solid.
[0296] LCMS: Purity >95%, [M+H] + 462.3.
[0297] 1H NMR (400 MHz, DMSO-d6) δ 11.81-11.90 (m, 1H), 11.03 (s, 1H), 8.24 (s, 1H), 7.80 (d, J=8.25 Hz, 1H), 7.72 (d, J=2.02 Hz, 2H), 7.58 (d, J=1.41 Hz, 1H), 7.36 (dd, J=1.50, 8.28 Hz, 1H), 6.68 (d, J=2.26 Hz, 1H), 4.84 (t, J=4.71 Hz, 1H), 4.72 (t, J=4.71 Hz, 1H), 4.43 (t, J=4.71 Hz, 1H), 4.36 (t, J=4.71 Hz, 1H), 1.77 (s, 9H).
[0298] Example 30 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-pyridyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 3-aminopyridine instead of 2-aminothiazole to yield (25 mg, 100%) as a yellow solid.
[0299] LCMS: Purity >95%, [MH] - 427.3.
[0300] 1 H NMR (400 MHz, DMSO-d6) δ 11.93-12.04 (m, 1H), 10.50 (s, 1H), 8.99 (d, J=2.20 Hz, 1H), 8.34 (dd, J=1.44, 4.68 Hz, 1H), 8.21-8.27 (m, 2H), 7.87 (d, J=8.25 Hz, 1H), 7.75 (s, 1H), 7.54 (d, J=1.41 Hz, 1H), 7.37-7.47 (m, 2H), 1.78 (s, 9H).
[0301] Example 31 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-pyridyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 4-aminopyridine instead of 2-aminothiazole to yield (22 mg, 9%) as a yellow solid.
[0302] LCMS: Purity >95%, [MH] - 427.3.
[0303] 1 H NMR (400 MHz, DMSO-d6) δ 11.98-12.05 (m, 1H), 10.60 (s, 1H), 8.48-8.53 (m, 2H), 8.25 (s, 1H), 7.88 (d, J=8.31 Hz, 1H), 7.81-7.85 (m, 2H), 7.75 (s, 1H), 7.58 (d, J=1.34 Hz, 1H), 7.40 (dd, J=1.44, 8.28 Hz, 1H), 1.78 (s, 9H).
[0304] Example 32 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-hydroxyethyl)pyrazol-3-yl]-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 2-(3-amino-1H-pyrazol-1-yl)ethan-1-ol instead of 2-aminothiazole to yield (15 mg, 7%) as a beige solid.
[0305] LCMS: Purity >95%, [MH] - 460.3.
[0306] 1H NMR (400 MHz, DMSO-d6) δ 11.81-11.88 (m, 1H), 10.99 (s, 1H), 8.26 (s, 1H), 7.80 (d, J=8.25 Hz, 1H), 7.72 (s, 1H), 7.65 (d, J=2.20 Hz, 1H), 7.57 (d, J=1.41 Hz, 1H), 7.36 (dd, J=1.47, 8.25 Hz, 1H), 6.64 (d, J=2.26 Hz, 1H), 4.10 (t, J=5.65 Hz, 2H), 3.75 (t, J=5.59 Hz, 2H), 1.78 (s, 9H).
[0307] Example 33 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-chloro-N-methyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-3-chloro-1H-indole-2-carboxylic acid and methylamine hydrochloride instead of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 2-aminothiazole to yield (14 mg, 14%) as a white solid.
[0308] LCMS: Purity >95%, [MH]-396.2.
[0309] 1 H NMR (300 MHz, DMSO-d6) δ 12.07 (br s, 1H), 8.25 (s, 1H), 7.97 (q, J=4.43 Hz, 1H), 7.70-7.78 (m, 2H), 7.47 (d, J=8.18 Hz, 1H), 2.90 (d, J=4.62 Hz, 3H), 1.75-1.90 (m, 9H).
[0310] Example 34 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and cyclopropylmethanamine instead of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 2-aminothiazole to yield (20 mg, 9%) as a white solid.
[0311] LCMS: Purity >95%, [M+H] + 376.3.
[0312] 1 H NMR (400 MHz, DMSO-d6) δ 8.25 (s, 1H), 7.80 (d, J=8.25 Hz, 1H), 7.74 (s, 1H), 7.36 (dd, J=1.53, 8.25 Hz, 1H), 7.19 (s, 1H), 5.08 (spt, J=6.63 Hz, 1H), 2.82-2.91 (m, 1H), 1.51 (d, J=6.72 Hz, 6H), 0.70-0.83 (m, 2H), 0.59-0.68 (m, 2H).
[0313] Example 35 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-fluoroethyl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 2-fluoroethylamine hydrochloride instead of 2-aminothiazole to yield (172 mg, 51%) as a brown solid.
[0314] LCMS: Purity >95%, [M+H] + 382.2.
[0315] 1 H NMR (400 MHz, DMSO-d6) δ 11.72-11.83 (m, 1H), 8.79 (t, J=5.62 Hz, 1H), 8.24 (s, 1H), 7.79 (d, J=8.31 Hz, 1H), 7.73 (s, 1H), 7.36 (dd, J=1.53, 8.25 Hz, 1H), 7.24 (dd, J=0.67, 2.02 Hz, 1H), 5.08 (spt, J=6.70 Hz, 1H), 4.64 (t, J=5.07 Hz, 1H), 4.52 (t, J=5.04 Hz, 1H), 3.62 (qd, J=5.32, 26.78 Hz, 2H), 1.51 (d, J=6.72 Hz, 6H).
[0316] Example 36 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethoxy-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and O-ethylhydroxylamine instead of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 2-aminothiazole to yield (68 mg, 60%) as a beige solid.
[0317] LCMS: Purity >95%, [M+H] + 380.2.
[0318] 1 H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 11.74 (br s, 1H), 8.25 (s, 1H), 7.79 (d, J=8.31 Hz, 1H), 7.72 (s, 1H), 7.37 (dd, J=1.47, 8.25 Hz, 1H), 7.10 (s, 1H), 5.08 (spt, J=6.71 Hz, 1H), 3.98 (q, J=6.97 Hz, 2H), 1.51 (d, J=6.66 Hz, 6H), 1.23-1.27 (m, 3H).
[0319] Example 37 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid instead of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid to yield (42 mg, 10%) as a yellow solid.
[0320] LCMS: Purity >95%, [M+H] + 419.2.
[0321] 1 H NMR (400 MHz, DMSO-d6) δ 12.76 (br s, 1H), 12.06 (br s, 1H), 8.25 (s, 1H), 7.85 (d, J=8.31 Hz, 1H), 7.77 (s, 1H), 7.75 (br s, 1H), 7.58 (d, J=3.55 Hz, 1H), 7.42 (dd, J=1.47, 8.25 Hz, 1H), 7.30 (d, J=3.48 Hz, 1H), 5.09 (spt, J=6.70 Hz, 1H), 1.52 (d, J=6.66 Hz, 6H).
[0322] Example 38 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-methylpyrazol-3-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 1-methyl-1H-pyrazol-3-amine instead of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 2-aminothiazole to yield (49 mg, 26%) as a white solid.
[0323] LCMS: Purity >95%, [M+H] + 416.2.
[0324] 1H NMR (400 MHz, DMSO-d6) δ 11.81-11.88 (m, 1H), 10.96 (s, 1H), 8.25 (s, 1H), 7.80 (d, J=7.94 Hz, 1H), 7.74 (s, 1H), 7.63 (d, J=2.14 Hz, 1H), 7.56 (d, J=1.34 Hz, 1H), 7.38 (dd, J=1.50, 8.28 Hz, 1H), 6.63 (d, J=2.20 Hz, 1H), 5.08 (spt, J=6.70 Hz, 1H), 3.81 (s, 3H), 1.51 (d, J=6.66 Hz, 6H).
[0325] Example 39 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 1 using 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 1,3,4-thiadiazol-2-amine instead of 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxylic acid and 2-aminothiazole to yield (3 mg, 2%) as a brown solid.
[0326] LCMS: Purity >95%, [M+H] + 420.1.
[0327] 1H NMR (400 MHz, DMSO-d6) δ 11.94 (br s, 1H), 9.08 (br s, 1H), 8.25 (s, 1H), 8.21 (s, 1H), 7.83 (d, J=8.31 Hz, 1H), 7.77 (s, 1H), 7.58 (br s, 1H), 7.39 (br d, J=8.25 Hz, 1H), 5.08 (quin, J=6.71 Hz, 1H), 1.52 (d, J=6.72 Hz, 6H).
[0328] Example 40 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide [ka] A mixture of 6-bromo-N-methyl-1H-indole-2-carboxamide (253 mg, 1 mmol), XPhos-Pd-G2 (16 mg, 0.02 mmol), XPhos (19 mg, 0.04 mmol), B2(OH)4 (269 mg, 3 mmol) and KOAc (294 mg, 3 mmol) in EtOH (10 ml) was degassed with argon for 5 min and then heated at 80° C. for 2 h. A degassed aqueous solution of K2CO3 (1.8 M, 1.7 ml, 3.0 mmol) and a degassed solution of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (270 mg, 1.0 mmol) in THF (2 ml) were added and the mixture was heated at 80° C. for 18 h. The reaction was cooled to room temperature, diluted with water and extracted with EtOAc (3x). The combined organic phases were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash column chromatography to give 204 mg of a solid which was further purified by preparative HPLC to give 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide (76 mg, 21%) as a white solid.
[0329] LCMS: Purity >95%, [MH]- 362.2.
[0330] 1 H NMR (400 MHz, DMSO-d6) δ 11.74 (s, 1H), 8.52 (q, J=4.42 Hz, 1H), 8.24 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.70 (s, 1H), 7.33 (dd, J=1.50, 8.22 Hz, 1H), 7.14 (d, J=1.28 Hz, 1H), 2.84 (d, J=4.65 Hz, 3H), 1.77 (s, 9H).
[0331] Example 41 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropyl-1H-indole-2-carboxamide [ka] Prepared as described for example 40 using 6-bromo-N-cyclopropyl-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield (78 mg, 31%) as a white solid.
[0332] LCMS: Purity >95%, [MH] - 390.2.
[0333] 1 H NMR (400 MHz, DMSO-d6) δ 11.71 (s, 1H), 8.52 (d, J=4.10 Hz, 1H), 8.24 (s, 1H), 7.76 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.33 (dd, J=1.47, 8.25 Hz, 1H), 7.17 (d, J=1.28 Hz, 1H), 2.87 (qq, J=3.90, 7.30 Hz, 1H), 1.77 (s, 9H), 0.67-0.77 (m, 2H), 0.57-0.67 (m, 2H).
[0334] Example 42 - 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethyl-1H-indole-2-carboxamide [ka] Prepared as described for example 40 using 6-bromo-N-ethyl-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield (77 mg, 31%) as a white solid.
[0335] LCMS: Purity >95%, [MH]-378.2.
[0336] 1 H NMR (400 MHz, DMSO-d6) δ 11.66-11.77 (m, 1H), 8.54 (t, J=5.59 Hz, 1H), 8.20-8.26 (m, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.33 (dd, J=1.50, 8.22 Hz, 1H), 7.17 (d, J=1.28 Hz, 1H), 3.33-3.38 (m, 2H), 1.77 (s, 9H), 1.16 (t, J=7.21 Hz, 3H).
[0337] Example 43 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclobutyl-1H-indole-2-carboxamide [ka] Prepared as described for example 40 using 6-bromo-N-cyclobutyl-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield (93 mg, 30%) as a white solid.
[0338] LCMS: Purity 85~90%, [MH]- 404.3.
[0339] 1 H NMR (400 MHz, DMSO-d6) δ 11.71 (br s, 1H), 8.69 (d, J=7.76 Hz, 1H), 8.24 (s, 1H), 7.78 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.34 (dd, J=1.50, 8.22 Hz, 1H), 7.24 (d, J=1.00 Hz, 1H), 4.47 (br d, J=8.31 Hz, 1H), 2.21-2.32 (m, 2H), 2.03-2.16 (m, 2H), 1.77 (s, 9H), 1.67-1.75 (m, 2H).
[0340] Example 44 - 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 40 using 6-bromo-N-methoxy-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxamide (17 mg, 5%) as a white solid rather than the expected 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methoxy-1H-indole-2-carboxamide.
[0341] LCMS: Purity >95%, [MH] - 350.2.
[0342] 1H NMR (400 MHz, DMSO-d6) δ 11.66-11.75 (m, 1H), 8.24 (s, 1H), 8.02 (br s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.42 (br s, 1H), 7.33 (dd, J=1.50, 8.22 Hz, 1H), 7.20 (d, J=1.34 Hz, 1H), 1.77 (s, 9H). Example 45 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-fluoro-N-methyl-1H-indole-2-carboxamide [ka] Prepared as described for example 40 using 6-bromo-3-fluoro-N-methyl-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield (12 mg, 17%) as a white solid. LCMS: Purity >95%, [M+H] + 382.2. 1 H NMR (400 MHz, DMSO-d6) δ 11.62 (s, 1H), 8.24 (s, 1H), 7.85-7.97 (m, 1H), 7.77 (d, J=8.38 Hz, 1H), 7.65 (s, 1H), 7.40 (dd, J=1.34, 8.38 Hz, 1H), 2.86 (d, J=4.58 Hz, 3H), 1.77 (s, 9H).
[0343] Example 46 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N,3-dimethyl-1H-indole-2-carboxamide [ka] Prepared as described for example 40 using 6-bromo-N,3-dimethyl-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield (28 mg, 20%) as a white solid.
[0344] LCMS: Purity >95%, [M+H] + 378.2.
[0345] 1 H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.24 (s, 1H), 7.89 (q, J=4.30 Hz, 1H), 7.75 (d, J=8.19 Hz, 1H), 7.63 (s, 1H), 7.33 (dd, J=1.47, 8.25 Hz, 1H), 2.84 (d, J=4.58 Hz, 3H), 2.52-2.55 (m, 3H), 1.77 (s, 9H).
[0346] Example 47 - 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,5-dimethylpyrazol-3-yl)-1H-indole-2-carboxamide [ka] Prepared as described for Example 40 using 6-bromo-N-(1,3-dimethyl-1H-pyrazol-5-yl)-1H-indole-2-carboxamide instead of 6-bromo-N-methyl-1H-indole-2-carboxamide to yield (27 mg, 5%) as a white solid.
[0347] LCMS: Purity >95%, [MH] - 444.3.
[0348] 1H NMR (400 MHz, DMSO-d6) δ 12.01 (br s, 1H), 10.25-10.45 (m, 1H), 8.25 (s, 1H), 7.85 (d, J=8.18 Hz, 1H), 7.73 (s, 1H), 7.46 (s, 1H), 7.39 (dd, J=1.43, 8.27 Hz, 1H), 6.06 (s, 1H), 3.65 (s, 3H), 2.15 (s, 3H), 1.77 (s, 9H).
[0349] Example 48 - 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 40 using 3-bromo-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine instead of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine to yield (81 mg, 39%) as a white solid.
[0350] LCMS: Purity >95%, [M+H] + 350.3.
[0351] 1 H NMR (400 MHz, DMSO-d6) δ 11.68-11.81 (m, 1H), 8.53 (q, J=4.44 Hz, 1H), 8.24 (s, 1H), 7.77 (s, 1H), 7.72 (s, 1H), 7.35 (dd, J=1.50, 8.22 Hz, 1H), 7.15 (d, J=1.28 Hz, 1H), 5.08 (spt, J=6.69 Hz, 1H), 2.84 (d, J=4.65 Hz, 3H), 1.51 (d, J=6.66 Hz, 6H).
[0352] Example 49 - 6-(4-amino-1-ethyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 40 using 3-bromo-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine instead of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine to yield (23 mg, 17%) as a white solid.
[0353] LCMS: Purity >95%, [M+H] + 336.2.
[0354] 1 H NMR (400 MHz, DMSO-d6) δ 11.72-11.82 (m, 1H), 8.53 (q, J=4.44 Hz, 1H), 8.25 (s, 1H), 7.78 (d, J=8.43 Hz, 1H), 7.72 (s, 1H), 7.35 (dd, J=1.50, 8.22 Hz, 1H), 7.14 (d, J=1.34 Hz, 1H), 4.39 (q, J=7.21 Hz, 2H), 2.84 (d, J=4.58 Hz, 3H), 1.43 (t, J=7.21 Hz, 3H).
[0355] Example 50 - 6-(4-amino-1-cyclopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide [ka] Prepared as described for Example 40 using 3-bromo-1-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine instead of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine to yield (36 mg, 23%) as a white solid.
[0356] LCMS: Purity >95%, [M+H] + 348.3.
[0357] 1 H NMR (400 MHz, DMSO-d6) δ 11.71-11.81 (m, 1H), 8.53 (q, J=4.52 Hz, 1H), 8.26 (s, 1H), 7.77 (d, J=8.25 Hz, 1H), 7.69 (s, 1H), 7.32 (dd, J=1.53, 8.25 Hz, 1H), 7.14 (d, J=1.34 Hz, 1H), 3.87 (tt, J=3.77, 7.35 Hz, 1H), 2.83 (d, J=4.58 Hz, 3H), 1.16-1.27 (m, 2H), 1.03-1.16 (m, 2H).
[0358] The following compounds were prepared in a manner similar to that described above, using synthetic procedures similar to those detailed for Example 40: [Table 4-1] [Table 4-2]
[0359] Example 60 - Biological Data RET and KDR enzyme assays Kinase activity was detected using the CisBio HTRF kinEASE kit, which is based on time-resolved fluorescence transfer (FRET). Assays were performed in 384-well white plates (Corning #3574) in a reaction volume of 10 μL containing 1X CisBio enzyme buffer supplemented with a final concentration of 5 mM MgCl2, 1 mM DTT, 10 nM SEB, and for RET, 0.01% Triton X100. The same buffer was used for the KDR biochemical assay with the addition of 2 mM MnCl2.
[0360] Inhibitors were pre-incubated in the plate for 15 min with 5 μL of kinase and assay buffer at the following concentrations: 13 pM RET (Carna Biosciences; 08-159) and 150 pM KDR (Millipore; 14-630). Reactions were started by the addition of 5 μL of ATP and 2x the final reaction concentration of substrate. For RET this was 18 μM and 2 μM; for KDR this was 16 μM and 1 μM, respectively. Reactions were run on ATP K for each target. m The assay was allowed to proceed at room temperature for 20 min before Eu 3+ The plate was terminated by the addition of 10 μL of HTRF detection buffer containing EDTA supplemented with TK-cryptate (1:100 dilution) and TK-antibody labeled with streptavidin-XL665 (128 nM). After 1 h incubation at room temperature, the FRET signal was measured using a Pherastar FS Microplate Reader.
[0361] Activity data (IC50) for compounds of the invention against the RET and KDR enzymes is shown in Table 1 below. [Table 5-1] [Table 5-2]
[0362] BaF3 cell assay Daley and Baltimore 16 We used a system originally developed by Pasi Janne, whereby IL3-dependent BaF3 cells were engineered to express an activated recombinant kinase. After removal of IL3, the engineered cells depend on the activity of the recombinant kinase for survival and proliferation. KIF5B-RET ( 7BaF3 cell lines expressing IL-16 (a gift from Sigma-Aldrich, NY) and KDR (Advanced Cellular Dynamics, San Diego) were maintained in RPMI-1640 medium containing 10% FBS and appropriate antibiotics. Unmodified BaF3 cells (WT type) were maintained in RPMI-1640 medium containing 10% FBS and supplemented with 10 ng / mL recombinant mouse IL3 (R&D systems). For compound IC50 evaluation, cells were plated in 384-well plates at 1500 or 3000 cells per well in 30 μL of medium and compounds were dispensed using an acoustic liquid handling platform (LABCYTE). Cells were incubated at 37°C for 48 h in a humidified 5% CO2 atmosphere, after which viability was determined by adding 10 μL of CellTiter-Glo reagent (Promega) and measuring luminescence.
[0363] The cell activity data is shown in Table 2 below. [Table 6-1] [Table 6-2]
[0364] Although particular embodiments of the present invention have been described herein for purposes of reference and example, various modifications will be apparent to those skilled in the art without departing from the scope of the invention, which is defined by the appended claims.
[0365] References [1]Carlomagno,F.,Guida,T.,Anagantil,S.,Vecchio,G.,Fusco,A.,Ryan,A.,Billaud,M.,Santoro,M.(2004).Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.Oncogene 23,6056-6063 [2]Chao,B.,Briesewitz,R.,Villalona-Calero,M.(2012) RET fusion genes in Non-Small-Cell Lung Cancer.JCO 30,4439-4441. [3]Diner,P.,Alao,J.,Soderland,J.,Sunnerhagen,P.Grotli,M.(2012) J Med Chem 2012 55 (10) 4872-6 [4]Elisei,R.,Cosci,B.,Romei,C.,Bottici,V.,Renzini,G.,Molinaro,E.,Agate,L.,Vivaldi,A.,Faviana,P.,Basolo,F.,Miccoli,P.,Berti,P.,Pacini,F.,Pinchera,A.(2008) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. Journal of Clinical Endocrinology and Metabolism 93,682-687. [5]Ju, Y., Lee, W., Shin, J., Lee, S., Bleazard, T., Won, J., Kim, Y., Kim, J., Kang, J., Seo, J. (2011). Res.3,436–445. [6]Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., Iwakawa, R., Ogiwara, H., Oike, T., Enari, M., Schet ter , A. , Okayama , H. , Haugen , A. , Skaug , V. Chiku , S. , Yamanaka , I. , Arai , Y. , Watanabe , S. , Sekine , I. , Ogawa , S. , Harris , C. , Tsuda , H. , Yoshida , T. , Yokota , J. , Shibata , T. (2012). KIF5B-RET fusions in lung adenocarcinoma. Nat Med.12,375–377. [7]Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jaroszi, M., Curran, J., Balasubramanian, S., Bloom, T., Brennan, K., Donahue, A., Downing, S., Frampton, G., Garcia, L., Juhn, F., Mitc hell , K. , White , E. , White , J. , Zwirko , Z. , Peretz , T. , Nechushtan , H. , Soussan-Gutman , L. , Kim , J. , S. et al asaki , H. , Kim , H. , Park , S. , Ercan , D. , Sheehan , C. , Ross , J. Cronin , M. , Janne , P. , Stephens , P. (2012). Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.Nat Med.12,382-384. [8]Matsubara, D., Kanai, Y., Ishikawa, S., Ohara, S., Yoshimoto, T., Sakatani, T., Oguni, S., Tamura, T., Kataoka, H., Endo, S., Murakami, Y., Aburatani, H., Fukayama, M., Niki, T. (2012). CCDC6-RET fusion in the human lung adenocarcinoma cell line,LC-2 / ad.J Thorac Oncol.12,1872-6. [9]Nagilla,M.,Brown,R.,Cohen,E.(2012).Cabozantinib for the treatment of advanced medullary thyroid cancer.Adv Ther 11,925-934.
[10] Santoro,M.and Carlomagno,F.(2006).Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.Nature Clinical Practice: Endocrinology and Metabolism 2,42-52.
[11] Verbeek.H.H.,Alves,M.M.,de Groot,J.W.,Osinga J,Plukker,J.T.,Links,T.P.,Hofstra,R.M.(2011).The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.J Clin Endocrinol Metab.96,2010-2381.
[12] Vitagliano,D.,De Falco,V.,Tamburrino,A.,Coluzzi,S.,Troncone,G.,Chiappetta,G.,Ciardiello,F.,Tortora,G.,Fagin,J.,Ryan,A.,Carlomagno,F.,Santoro,(2011).The tyrosine inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Endocrine-related Cancer 18,1-11.
[13] Wang,R.,Hu,H.,Pan,Y.,Li,Y.,Ye,T.,Li,C.,Luo,X.,Wang,L.,Li,H.,Zhang,Y.,Li,F.,Lu,Y.,Lu,Q.,Xu,J.,Garfield,D.,Shen,L.,Ji,H.,Pao,W.,Sun,Y.,Chen,H.(2012).RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.JCO 30,4352-4359.
[14] Wells,S.and Santoro,M.(2009) Targeting the RET pathway in thyroid cancer.Clin Can Res.15,7119-7123.
[15] Wells,S.,Gosnell,J.,Gagel,R.,Moley,J.,Pfister,D.,Sosa,J.,Skinner,M.,Krebs,A.,Vasselli,J.,Schlumberger,M.(2012).Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized,double-blind phase III trial.JCO 10,134-141.
[16] Daley,G.Q.;Baltimore,D.Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr / abl protein.Proc.Natl.Acad.Sci.U.S.A.1988,85,9312-16.
Claims
1. A compound having the structural formula (I) as shown below, or a pharma- ceutically acceptable salt, hydrate or solvate thereof: [Formula 1] (In the formula: HET is selected from one of the following: [Case 2] (In the formula, [C3] indicates the point of attachment; R 1 is hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -L-Y-Q wherein the group is selected from the group consisting of: L is absent or is a (1-5C)alkylene optionally substituted by one or more substituents selected from a (1-2C)alkyl or an oxo; Y is absent or is O, S, SO, SO 2 , N(R a ), C(O), C(O)O, OC(O), C(O)N(R a ), N(R a ) C(O), N(R a ) C(O)N(R b ), N(R a )C(O)O, OC(O)N(R a ), S(O) 2 N (R a ), or N(R a ) S.O. 2 (In the formula, R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d ) R c , N(R d ) C(O)R c , S(O) y R c (y is 0, 1 or 2), SO 2 N (R d ) R c , N(R d ) S.O. 2 R c , Si(R d ) (R c ) R e Or (CH 2 ) z N.R. d R c (z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; or R c and R d may be linked together with the nitrogen atom to which they are attached such that they form a 4- to 7-membered heterocyclic ring optionally substituted by one or more substituents selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano or hydroxy; or Q is a group of the formula: -L 1 -L Q1 -Z 1 wherein the formula: L 1 is absent or is a (1-3C)alkylene optionally substituted by one or more substituents selected from a (1-2C)alkyl or an oxo; L Q1 is absent or O, S, SO, SO 2 , N(R f ), C(O), C(O)O, OC(O), C(O)N(R f ), N(R f ) C(O), N(R g ) C(O)N(R f ), N(R f )C(O)O, OC(O)N(R f ), S(O) 2 N (R f ), or N(R f ) S.O. 2 (In the formula, R f and R g are each independently selected from hydrogen or (1-2C)alkyl; Z 1 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z 1 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR h R i , OR h , C(O)R h , C(O)OR h , O.C.(O)R h , C(O)N(R i ) R h , N(R i ) C(O)R h , S(O) y R h (y is 0, 1 or 2), SO 2 N (R i ) R h , N(R i ) S.O. 2 R h Or (CH 2 ) z N.R. i R h (z is 1, 2 or 3); h and R i are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); R 1a and R 1b are each selected from H, (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl or mercapto; W is O, S or NR 1 (In the formula, R 1 is selected from H or (1-2C)alkyl); Bonds a, b, c and d are independently selected from a single bond or a double bond; X 1 and X 2 each independently represents N or CR when bond a is a double bond; j or NR when bond a is a single bond. k Or CR j R k Selected from: (In the formula, R j is hydrogen, halo, (1-4C) alkyl, (1-4C) alkoxy, amino, (1-4C) alkylamino, (1-4C) dialkylamino, cyano, (2C) alkynyl, C(O)R j1 , C(O)OR j1 , O.C.(O)R j1 , C(O)N(R j2 ) R j1 , N(R j2 ) C(O)R j1 , S(O) y R j1 (y is 0, 1 or 2), SO 2 N (R j2 ) R j1 , N(R j2 ) S.O. 2 R j1 Or (CH 2 ) z N.R. j1 R j2 (z is 1, 2 or 3); said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R k and R j is independently selected from hydrogen or (1-4C)alkyl; R j1 and R j2 are each independently selected from hydrogen or (1-4C)alkyl; X 3 When bond b is a double bond, N or CR l or when bond b is a single bond, NR m Or CR l R m Selected from: (In the formula, R l is hydrogen, halo, (1-4C) alkyl, (1-4C) alkoxy, amino, (1-4C) alkylamino, (1-4C) dialkylamino, cyano, (2C) alkynyl, C(O)R l1 , C(O)OR l1 , O.C.(O)R l1 , C(O)N(R l2 ) R l1 , N(R l2 ) C(O)R l1 , S(O) y R l1 (y is 0, 1 or 2), SO 2 N (R l2 ) R l1 , N(R l2 ) S.O. 2 R l1 Or (CH 2 ) z N.R. l2 R l1 (z is 1, 2 or 3); said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R l and R m is independently selected from hydrogen or (1-4C)alkyl; R l1 and R l2 are each independently selected from hydrogen or (1-4C)alkyl; X 4 When bond d is a double bond, N or CR n or NR when bond d is a single bond. o Or CR n R o Selected from: (In the formula, R n is hydrogen, halo, (1-4C) alkyl, (1-4C) alkoxy, amino, (1-4C) alkylamino, (1-4C) dialkylamino, cyano, (2C) alkynyl, C(O)R n1 , C(O)OR n1 , O.C.(O)R n1 , C(O)N(R n2 ) R n1 , N(R n2 ) C(O)R n1 , S(O) y R n1 (y is 0, 1 or 2), SO 2 N (R n2 ) R n1 , N(R n2 ) S.O. 2 R n1 Or (CH 2 ) z N.R. n1 R n2 (z is 1, 2 or 3); said (1-4C)alkyl is optionally substituted by one or more substituents selected from amino, hydroxy, (1-2C)alkoxy or halo; R n and R o is independently selected from hydrogen or (1-4C)alkyl; R n1 and R n2 are each independently selected from hydrogen or (1-4C)alkyl; R 2 is hydrogen, (1-4C)alkyl or the formula: -L 2 -Y 2 -Q 2 wherein the group is selected from the group consisting of: L 2 is absent or is a (1-3C)alkylene optionally substituted by one or more substituents selected from a (1-2C)alkyl or an oxo; Y 2 is absent or is C(O), C(O)O, C(O)N(R p ) (wherein, R p is selected from hydrogen or (1-4C)alkyl; Q 2 is hydrogen, (1-6C)alkyl, aryl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q 2 is (1-4C) alkyl, halo, (1-4C) haloalkyl, (1-4C) haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR q R r , OR q (In the formula, R q and R r are optionally further substituted by one or more substituents independently selected from: hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; R 3 is the formula: -Y 3 -Q 3 wherein the group is selected from the group consisting of: Y 3 is C(O), C(O)N(R s ), N(R s )(O)C,C(O)OR s , O.C.(O)CR s , triazole, oxadiazole or tetrazole (wherein R s is selected from hydrogen or (1-2C)alkyl; Q 3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q 3 is (1-4C) alkyl, halo, (1-4C) haloalkyl, (1-4C) haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q 3 is the formula: -L 4 -L Q4 -Z 4 wherein the formula: L 4 is absent or is a (1-3C)alkylene optionally substituted by one or more substituents selected from a (1-2C)alkyl or an oxo; L Q4 is absent or O, S, SO, SO 2 , N(R v ), C(O), C(O)O, OC(O), C(O)N(R v ), N(R v ) C(O), N(R w ) C(O)N(R v ), N(R v )C(O)O, OC(O)N(R v ), S(O) 2 N (R v ), or N(R v ) S.O. 2 (In the formula, R v and R w are each independently selected from hydrogen or (1-2C)alkyl; Z 4 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z 4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR x R y , OR x , C(O)R x , C(O)OR x , O.C.(O)R x , C(O)N(R y ) R x , N(R y ) C(O)R x , S(O) y R x (y is 0, 1 or 2), SO 2 N (R y ) R x , N(R y ) S.O. 2 R x Or (CH 2 ) z N.R. x R y (z is 1, 2 or 3); x and R y are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl); However, X 1 , X 2 , X 3 or X 4 can be N).
2. HET is as follows: [C4] (In the formula, R 1 , W and R 1b are each as defined in claim 1.
2. The compound of claim 1, selected from one of:
3. The compound has the structural formula Ib shown below: [C5] (In the formula, R 1 , bonds a, b, c and d, X 1 , X 2 , X 3 , X 4 , R 2 , Q 3 And R s are each as defined in claim 1.
3. The compound of claim 1 or 2, having the formula:
4. X 1 and X 2 are each independently N or CR j Bond a is a double bond; R j The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein is selected from hydrogen, halo, (1-4C)alkyl or amino.
5. X 3 is N or CR l bond b is a double bond; R l The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein is selected from hydrogen, halo, (1-4C)alkyl or amino.
6. X 4 is N or CR n bond d is a double bond; R n is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, amino, (1-4C)alkylamino, (1-4C)dialkylamino or cyano, (2C)alkynyl, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
7. The compound has the structural formula Id: [C6] (In the formula, R 1 , X 4 , R 2 and Q. 3 are each as defined in claim 1. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
8. X 4 is CR n and R n The compound of claim 7, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, wherein is selected from hydrogen, halo, (1-4C)alkyl or amino.
9. R 1 is hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy or a group of the formula: -L-Y-Q (In the formula: L is absent or is a (1-3C)alkylene optionally substituted by one or more substituents selected from a (1-2C)alkyl or an oxo; Y is absent or is C(O), C(O)O, OC(O), C(O)N(R a ) or N(R a )C(O) (wherein, R a and R b are each independently selected from hydrogen or (1-4C)alkyl; Q is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; Q is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d ) R c , N(R d ) C(O)R c , S(O) y R c(y is 0, 1 or 2), SO 2 N (R d ) R c , N(R d ) S.O. 2 R c , Si(R d ) (R c ) R e Or (CH 2 ) z N.R. d R c (z is 1, 2, or 3); c , R d and R e are each independently selected from hydrogen, (1-6C)alkyl, or (3-6C)cycloalkyl. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
10. R 1 is selected from hydrogen, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-10C)cycloalkyl, (3-10C)cycloalkenyl, heteroaryl or heterocyclyl; each of said substituents is selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, NR c R d , OR c , C(O)R c , C(O)OR c , O.C.(O)R c , C(O)N(R d ) R c , N(R d ) C(O)R c , S(O) y R c (y is 0, 1 or 2), SO 2 N (R d ) R c , N(R d ) S.O. 2 R c , Si(R d ) (R c ) R e Or (CH 2 ) z N.R. d R c (z is 1, 2, or 3); c , R d and R e or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
11. R 1 is selected from hydrogen, (1-6C)alkyl or (3-10C)cycloalkyl; each of said substituents is selected from (1-4C)alkyl, halo, amino, (1-4C)aminoalkyl, cyano, hydroxy, carboxy, NR c R d , OR c Or Si(R d ) (R c ) R e and optionally further substituted by one or more substituents independently selected from c , R d and R e is independently selected from hydrogen or (1-4C)alkyl, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
12. R 2 is hydrogen, (1-4C)alkyl or the formula: -Y 2 -Q 2 (In the formula: Y 2 is C(O)N(R p ) (wherein, R p is selected from hydrogen or (1-4C)alkyl; Q 2is (1-6C)alkyl, aryl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; Q 2 is optionally further substituted by one or more substituents independently selected from (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, amino, cyano, or hydroxy. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
13. R 2 is hydrogen, or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
14. Q 3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Q 3 is (1-4C) alkyl, halo, (1-4C) haloalkyl, (1-4C) haloalkoxy, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, NR t R u , OR t (In the formula, R t and R u are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl; or Q 3 is the formula: -L 4 -L Q4 -Z 4 (In the formula: L 4 is absent or is a (1-3C)alkylene optionally substituted by one or more substituents selected from a (1-2C)alkyl or an oxo; L Q4 is absent or O, N(R v), C(O), C(O)O, OC(O), C(O)N(R v ), N(R v )C(O), S(O) 2 N (R v ), or N(R v ) S.O. 2 (In the formula, R v and R w are each independently selected from hydrogen or (1-2C)alkyl; Z 4 is hydrogen, (1-6C)alkyl, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkenyl, heteroaryl or heterocyclyl; Z 4 is (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxy, (1-4C)alkylamino, amino, cyano, hydroxy, carboxy, carbamoyl, sulfamoyl, mercapto, ureido, aryl, heteroaryl, heterocyclyl, (3-6C)cycloalkyl, NR x R y , OR x and optionally substituted with one or more substituents selected from: x and R y are each independently selected from hydrogen or (1-4C)alkyl. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
15. Q 3 is hydrogen, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-2C)alkyl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; Q 3 is (1-4C) alkyl, halo, (1-4C) haloalkyl, amino, cyano, hydroxy, NR t R u , OR t (In the formula, R t and R uare each independently selected from hydrogen or (1-4C)alkyl; or Q is optionally further substituted by one or more substituents independently selected from 3 is the formula: -L 4 -L Q4 -Z 4 (In the formula: L 4 is absent or is (1-2C)alkylene; L Q4 is absent or selected from O; Z 4 is hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl; Z 4 is (1-4C) alkyl, halo, (1-4C) haloalkyl, (1-4C) alkoxy, amino, hydroxy, (3-6C) cycloalkyl, NR x R y , OR x and optionally substituted with one or more substituents selected from: x and R y are each independently selected from hydrogen or (1-4C)alkyl. or a pharma- ceutically acceptable salt, hydrate or solvate thereof.
16. below: 6-(4-amino-1-cyclopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-ethyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,5-dimethylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N,3-dimethyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-fluoro-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclobutyl-1H-indole-2-carboxamide; 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-methylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethoxy-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-fluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-3-chloro-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-hydroxyethyl)pyrazol-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-pyridyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-pyridyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-fluoroethyl)pyrazol-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-[1-(2-methoxyethyl)pyrazol-3-yl]-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-ethylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4-methylthiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isoxazol-4-yl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-5-yl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(3-thienyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,2,4-thiadiazol-5-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-hydroxyethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-phenyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methoxyethoxy)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1-methylpyrazol-3-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(1,3,4-thiadiazol-2-yl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(cyclopropylmethoxy)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-ethoxy-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,2-difluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2,2,2-trifluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(cyclopropylmethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-phenethyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-benzyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isobutyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-fluoroethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methoxy-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-propyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(2-methoxyethyl)-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-butyl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-thiazol-2-yl-1H-indole-2-carboxamide; 6-(4-amino-1-tert-butyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-isopropyl-1H-indole-2-carboxamide; 6-[4-amino-1-(3-hydroxy-3-methyl-cyclopentyl)pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-isopropyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N,3-dimethyl-1H-indole-2-carboxamide; 6-[4-amino-1-(3-methoxypropyl)pyrazolo[3,4-d]pyrimidin-3-yl]-N-methyl-1H-indole-2-carboxamide; 6-(4-amino-1-cyclobutyl-pyrazolo[3,4-d]pyrimidin-3-yl)-N-methyl-1H-indole-2-carboxamide; or tert-Butyl 3-[4-amino-3-[2-(methylcarbamoyl)-1H-indol-6-yl]pyrazolo[3,4-d]pyrimidin-1-yl]azetidine-1-carboxylate or a pharma- ceutically acceptable salt, hydrate or solvate thereof, selected from any one of:
17. 10. A compound according to any one of the preceding claims, or a pharma- ceutically acceptable salt or hydrate thereof, for use in therapy.
18. 17. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt or hydrate thereof, and a pharma- ceutically acceptable carrier or excipient.
19. A compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 18, for use in the treatment of cancer.
20. 20. The compound or pharmaceutical composition of claim 19, wherein the cancer is medullary thyroid carcinoma or non-small cell lung cancer.
21. A method for treating cancer in a subject in need of such treatment, said method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt or hydrate thereof, or a pharmaceutical composition according to claim 18.
22. 22. The method of claim 21, wherein the cancer is medullary thyroid cancer or non-small cell lung cancer.
Citation Information
Patent Citations
Concomitant use of igfr inhibitors and anticancer agents
JP2009520028A
Protein kinase inhibitors
JP2009522284A
Heterocyclic kinase inhibitors
JP2012503655A
Benzoxazole kinase inhibitors and methods of use
JP2012507522A
Specific chemical substances, compositions, and methods
JP2012533541A
